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ABSTRACT OF DISSERTATION 
ROLE OF MCP-1 AND CCR2 IN ETHANOL-INDUCED DAMAGE IN THE 
DEVELOPING BRAIN 
Fetal alcohol spectrum disorders (FASD) are caused by alcohol exposure during 
pregnancy and is the leading cause of mental retardation. Alcohol exposure during 
development results in the loss of neurons in the developing brain. The underlying 
molecular mechanisms are unclear and there currently is no cure for FASD. Ethanol-
induced neuronal death is accompanied by neuroinflammation. Chemokine monocyte 
chemoattractant protein 1 (MCP-1) and its receptor C-C chemokine receptor type 2 (CCR2) 
are critical mediators of neuroinflammation and microglial activation. Using a third 
trimester equivalent mouse model of ethanol exposure, we found that treatment of Bindarit 
(MCP-1 synthesis inhibitor) and RS504393 (CCR2 antagonist) significantly reduced 
ethanol-induced microglia activation/neuroinflammation, and neuroapoptosis in the 
developing brain. Moreover, ethanol plus MCP-1 caused more neuronal death in a 
neuron/microglia co-culture system than neuronal culture alone, and Bindarit and 
RS504393 attenuated ethanol-induced neuronal death in the co-culture system. Ethanol 
activated TLR4 and GSK3β, two key mediators of microglial activation in the brain and 
cultured microglial cells (SIM-A9). Blocking MCP-1/CCR2 signaling attenuated ethanol-
induced activation of TLR4 and GSK3β.  
Further, we determined whether knocking out of MCP-1/CCR2 ameliorates 
neonatal alcohol exposure-induced long-lasting behavioral deficits in adolescent and adult 
mice. C57BL/6 and MCP-1-/-/CCR2-/- mice were exposed to alcohol (5 g/kg) by 
subcutaneously injection on PD4. A series of behavioral tests including Open Field (PD 
35-36 and PD 70-71), Rotor-Rod (PD 38 and PD 73), Balance Beam (PD 40 and PD75) 
and Morris Water Maze (PD 42 and PD77) were performed in the adolescence and 
adulthood. We found that MCP-1-/-/CCR2-/- mice were resistant to neonatal alcohol 
exposure-induced deficits in motor function in the Rotor-Rod and Balance Beam tests; 
MCP-1 and CCR2 deficiency also protected mice against neonatal ethanol exposure 
induced long lasting deficits in learning and memory in the Morris Water Maze testing. 
Collectively, these results suggest that MCP-1/CCR2 signaling plays an important role in 
ethanol-induced microglial activation/neuroinflammation and neurodegeneration in the 
developing brain and also plays an important role in developmental alcohol exposure 
induced long-lasting behavioral deficits in adolescence and adulthood.    
Keywords 
Fetal alcohol syndrome, chemokines, development, glia, neuroinflammation, 
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CHAPTER 1: INTRODUCTION 
Maternal alcohol consumption during pregnancy may cause fetal alcohol spectrum 
disorders (FASD) which are characterized by a spectrum of physical, mental and 
behavioral disabilities with possible lifelong implications [2]. Fetal alcohol syndrome is 
the most severe form of FASD, and includes a group of pathological conditions, such as 
facial abnormalities, growth restrictions, learning/memory deficits, and defects of heart, 
kidney and bone [7]. Chronic alcohol exposure in adults results in neuronal degeneration 
and cognitive deficits [1]. However, the mechanisms underlying alcohol CNS 
neurotoxicity are unclear. 
Multiple mechanisms have been proposed, including endoplasmic reticulum (ER) 
stress [2], oxidative stress [3, 4], interference of signaling by neurotrophic factors and 
disruption of microRNAs [5]. Recently, neuroinflammation has been proposed to play an 
important role in the pathogenesis of FASD and AUD [6-8]. Alcohol-induced neuronal 
death is accompanied by microglial activation and neuroinflammation in both developing 
and adult brains [6, 7, 9, 10].  
MCP-1, also known as chemokine (CC motif) ligand 2 (CCL2), is an important 
chemokine that regulates neuroinflammation [11-13]. MCP-1 and its receptor C-C 
chemokine receptor type 2 (CCR2) are mainly detected in microglia in mouse and human 
brains. [11].  Astrocytes are another source for MCP-1 [14], and there are reports showing 
that MCP-1 and CCR2 are detected in neurons [15, 16]. MCP-1/CCR2 signaling has been 
implicated in several neuroinflammatory disorders, such as Alzheimer’s disease [17], 
multiple sclerosis [18] and ischemic brain damage [19]. MCP-1/CCR2 signaling is also 
involved in some models of alcoholism [20-22]. The administration of alcohol increases 
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the expression of MCP-1 in the rodent brain [23, 24] and genetic studies in animals indicate 
that elevated MCP-1 signaling is accompanied by increased alcohol consumption [25]. In 
human alcoholics, MCP-1 expression is augmented in the ventral tegmental area, substantia 
nigra, hippocampus and amygdala of the brain autopsy [22]. In this dissertation, we 
investigated the role of MCP-1/CCR2 signaling in developmental alcohol-induced 
neuroinflammation, neurodegeneration and behavioral deficits. I observed that MCP-1 
synthesis inhibitor Bindarit and CCR2 antagonist RS504393 each significantly inhibited 
alcohol-induced microglial activation/neuroinflammation and neuroapoptosis in the brain 
of early postnatal mouse pups. Besides, deficiency in MCP-1 and CCR2 made mice more 
resistant to alcohol-induced long lasting deficits in motor function and learning and 
memory. In addition to microglial activation and neuroinflammation, stimulation of MCP-
1/CCR2 signaling may cause neurotoxicity through other mechanisms [26].  
Recently studies have reported a synergistic effect between inflammation and ER 
stress, which may result in higher microglial activation and drive sustained inflammation 
[27]. However, it is unclear whether inflammation induces ER stress in microglia or 
reversely ER stress activates microglia and promotes inflammation. In this dissertation, I  
sought to determine whether LPS could cause ER stress and reversely whether ER stress 
induced by tunicamycin treatment could activate microglia cells and induce inflammation. 







CHAPTER 2: ROLE OF MCP-1 AND CCR2 IN ETHANOL-INDUCED 
NEUROINFLAMMATION AND NEURODEGENERATION IN THE DEVELOPING 
BRAIN 
Synopsis 
Background: Neuroinflammation and microglial activation have been implicated in both 
alcohol use disorders (AUD) and fetal alcohol spectrum disorders (FASD). Chemokine 
monocyte chemoattractant protein 1 (MCP-1) and its receptor C-C chemokine receptor 
type 2 (CCR2) are critical mediators of neuroinflammation and microglial activation. 
FASD is the leading cause of mental retardation in the US[28], and one of the most 
devastating outcomes of FASD is the loss of neurons in the central nervous system 
(CNS). The underlying molecular mechanisms, however, remain unclear. We 
hypothesize that MCP-1/CCR2 signaling mediates ethanol-induced neuroinflammation 
and microglial 
activation, which exacerbates neurodegeneration in the developing brain.  
Methods: C57BL/6 mice were exposed to ethanol on postnatal day 4 (PD4). 
Neuroinflammation, microglial activation, and neurodegeneration in the brain were 
evaluated by immunohistochemistry and immunoblotting. A neuronal and microglial co-
culture system was used to evaluate the role of microglia and MCP-1/CCR2 signaling in 
ethanol-induced neurodegeneration. Specific inhibitors were employed to delineate the 
involved signaling pathways. 
Results: Ethanol-induced microglial activation, neuroinflammation, and a drastic 
increase in the mRNA and protein levels of MCP-1. Treatment with Bindarit (MCP-1 
synthesis inhibitor) and RS504393 (CCR2 antagonist) significantly reduced ethanol-
induced microglia activation/neuroinflammation, and neuroapoptosis in the developing 
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brain. MCP-1−/− and CCR2−/− mice were more resistant to ethanol-induced 
neuroapoptosis. Moreover, ethanol plus MCP-1 caused more neuronal death in a 
neuron/microglia co-culture system than in a neuronal culture alone, and Bindarit and 
RS504393 attenuated ethanol-induced neuronal death in the co-culture system. Ethanol 
activated TLR4 and GSK3β, two key mediators of microglial activation in the brain and 
cultured microglial cells (SIM-A9). Blocking MCP-1/CCR2 signaling attenuated ethanol-
induced activation of TLR4 and GSK3β. 
Conclusion: MCP-1/CCR2 signaling played an important role in ethanol-induced 
microglial activation/neuroinflammation and neurodegeneration in the developing brain. 
The effects may be mediated by the interaction among MCP-1/CCR2 signaling, TLR4, 
and GSK3β. 
Keywords: Alcohol abuse, Apoptosis, Chemokines, Development, Glia, 
Neurodegeneration 
Introduction 
Fetal alcohol spectrum disorders (FASD) are a spectrum of defects that can present 
as physical, mental, and\or behavioral disabilities that stem from ethanol exposure 
during fetal development. FASD is estimated to affect as many as 2-5% of people and 
costs the United States more than $5 billion annually [29]. One of the most devastating 
effects of developmental exposure to ethanol is the permanent loss of neurons in the central 
nervous system (CNS) [30, 31]. Although significant progress has been achieved in this 
line of research, the underlying molecular mechanisms remain unclear. Ethanol-induced 
neuronal death is accompanied by microglial activation and neuroinflammation [21, 32-
34]. Monocyte chemoattractant protein 1 (MCP-1), also called chemokine (CC motif) 
ligand 2 (CCL2), is a key chemokine involved in neuroinflammation [11-13]. In mouse 
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and human brain, MCP-1 and its receptor CCR2 are primarily expressed by microglia [11]. 
Although inflammatory response represents one of the first immune processes that protect 
an organism against diseases following injury, prolonged and sustained inflammation may 
have cytotoxic effects, aggravating the incidence and the severity of the disease. Increased 
MCP-1 expression and microglial activation have been observed in the brain of human 
alcoholics [22]. It has been hypothesized that ethanol exposure may sensitize the immune 
system to subsequent insults and lead to excess neuroinflammation in alcohol use disorders 
(AUD) and FASD [6, 35]. It is also proposed that microglia primed by ethanol exposure 
may contribute to neurotoxicity observed in AUD and FASD [6, 35]. Elevated MCP-1 
levels have been observed in brains which undergo various pathogenesis processes, such 
as multiple sclerosis [36, 37], stroke [38, 39] and Alzheimer’s disease [40, 41], and it is 
believed that the up-regulation of MCP-1 is involved in the progression of these diseases 
[37, 38, 41]. Interestingly, the detrimental effects caused by overexpression of MCP-1 in 
those diseases were not observed in mice lacking CCR2 [42-45]. Therefore, MCP-1/CCR2 
signaling may play an important role in neuroinflammatory diseases. In this study, we 
sought to determine whether MCP-1/CCR2 signaling is involved in ethanol-induced 
microglial activation and neuroinflammation in the context of neurodegeneration in the 
developing brain. We used a well-established third trimester equivalent mouse model in 
which ethanol exposure caused wide spread neurodegeneration. We showed that inhibiting 
MCP-1/CCR2 signaling significantly reduced ethanol-induced microglial 
activation/neuroinflammation and ameliorated neurodegeneration in the developing brain. 
It appeared that ethanol-induced microglial activation/neuroinflammation was mediated by 
the interaction among MCP-1/CCR2 signaling, TLR4, and GSK3β.  
6 
Materials and Methods 
Reagents 
The inhibitor of MCP-1 synthesis, Bindarit, was purchased from Cayman chemical 
(Ann Arbor, MI, USA). CCR2 antagonist RS504393 was purchased from TOCRIS, Inc 
(Minneapolis, MN, USA). TLR4 inhibitor TAK242 was purchased from EMD Millipore, 
Inc (Burlington, MA, USA). GSK3β inhibitor SB-216763 was purchased from Sigma-
Aldrich, Inc (St. Louis, MO, USA). Anti-MCP-1 antibody was purchased from Bio-Rad 
AbD Serotec, Inc. (Raleigh, NC, USA). Anti-CCR-2 antibody was purchased from 
BioVision, Inc. (Milpitas, CA, USA). Anti-Iba-1 antibody was purchased from Wako 
Chemicals USA, Inc. (Richmond, VA, USA). All other antibodies were purchased from 
Cell Signaling Technology, Inc. (Beverly, MA, USA). Other chemicals/reagents used in 
this project were obtained from Thermo Fisher Scientific, Inc (Waltham, MA, USA) unless 
stated otherwise.  
Animals and ethanol exposure 
C57BL/6 mice, MCP-1−/− (B6.129S4-Ccl2tm1Rol/J) mice and CCR2−/− (B6.129S4-
Ccr2tm1Ifc/J) mice were obtained from Jackson Laboratories (Bar Harbor, Maine, USA). All 
animals were housed in a specific pathogen-free room within the animal facilities at the 
University of Kentucky, and handled according to the Institutional Animal Care and Use 
Committee (Protocol #: 2008-0401).  
Pups (male and female from 6 litters of mice) of postnatal day 4 (PD4) were 
weighed, and randomly assigned to six groups: control; ethanol (EtOH); Bindarit; 
RS504393; EtOH plus Bindarit; EtOH plus RS504393. Pups received a total of 5 g/kg 
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ethanol in two subcutaneous (SC) injections which were two hours apart; each contained 
ethanol (2.5 g/kg, 20% solution in saline) [2, 46]. We have previously determined that the 
blood alcohol concentration (BAC) was 338 mg/dl 8 hours after the first injection [2]. 
BACs greater than 300 mg/dl are not uncommon in human alcoholics [47-50]. Some 
alcoholics with a BAC> 400 mg/dl were coherent and able to drive [50]. BACs> 500 mg/dl 
have been reported in heavy drinkers [48, 49, 51]. Bindarit is an inhibitor of MCP-1 
synthesis and RS504393 is an antagonist for CCR2; they have been extensively used for 
blocking MCP-1/CCR2 signaling in vitro and in vivo [52, 53]. Bindarit (100 mg/kg) or 
RS504393 (1 mg/kg) were administered by two (SC) injections at 24 and 0.5 hours prior 
to ethanol exposure. The concentrations of Bindarit and RS504393 used in this study were 
based on previous publications [52, 53]. The control pups received an injection of equal 
volume of saline or DMSO, depending on whether it was an inhibitor or ethanol exposure. 
At 8 hours after the first ethanol injection, pups were sacrificed and the brains were 
dissected and processed for further analysis. A diagram showing Ethanol/inhibitor 
administration model is provided (Fig. 2.1). 
 
Fig. 2.1. Paradigm for ethanol and inhibitor administration. Mouse pups received two 
subcutaneous (SC) injections of ethanol which were 2 h apart; each contained ethanol 
(2.5 g/kg, 20% solution in saline). Bindarit (100 mg/kg) or RS504393 (1 mg/kg) was 






Culture of microglial cells and neurons 
Immortalized mouse microglia cells (SIM-A9) were purchased from American 
Type Culture Collection (ATCC) (Manassas, VA, USA). SIM-A9 cells are a spontaneously 
immortalized microglial cell line that exhibits key characteristics of cultured primary 
microglia [54]. SIM-A9 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM)/F12 medium supplemented with 5% horse serum, 10% fetal bovine serum (FBS), 
2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in 5% CO2 
in a humidified atmosphere. The culture medium was replaced with DMEM/F12 medium 
without FBS at 50-60% confluence overnight before indicated treatment. The cultures were 
exposed to ethanol (0.2%, 0.4%, or 0.8% V/V) in sealed containers. The containers were 
placed in a humidified environment and maintained at 37°C with 5% CO2. With this 
method, the ethanol concentration in the culture medium can be accurately maintained [55]. 
To block MCP-1/CCR2 signaling, SIM-A9 cells were exposed to Bindarit (300 µM) or 
RS504393 (100 µM) for 12 hours prior to ethanol treatment. The concentrations of Bindarit 
and RS504393 were based on previous publications [56, 57]. To block TLR4 or GSK3β 
signaling, SIM-A9 cells were exposed to TAK242 (1 µM) or SB 216763 (10 µM) for 12 
hours prior to ethanol treatment. The concentrations of TAK242 and SB 216763 were based 
on previous studies [58, 59].  Primary cortical and cerebellar neurons were generated from 
the brain of C57BL6 mice on postnatal day 1. The methods for the isolation and culture of 
primary cortical and cerebellar neurons have been previously described in detail [60, 61]. 
Briefly, the pups were decapitated and the brain immediately transferred into dissection 
medium (97.5% Hank’s balanced salt solution, 0.11 mg/ml sodium pyruvate, 0.1% 
glucose, 10 mM HEPES, 100 U/ml penicillin, and100 μg/ml streptomycin). The meninges 
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were removed and the cerebral cortices and cerebella dissected. Cerebral cortical tissues 
and cerebella were dissociated with 0.25% trypsin followed by 0.1% DNase treatment. 
Then, tissues were carefully triturated and the cell suspension was mixed with 4% bovine 
serum albumin and centrifuged. The cell pellet was resuspended in Neuronbasal/B27 
medium containing B27 (2%), glutamine (1 mM/L), penicillin (100 U/ml) and 
streptomycin (100 μg/ml). Cells were plated onto poly-D-lysine (50 μg/ml)-coated cell 
culture plates. The co-cultures of microglia cells and primary cortical neurons or cerebellar 
neurons were established in 24-well cell culture plates with inserts as described previously 
[62]. The cortical or cerebellar neurons were maintained in the cell culture plate containing 
500 μl of medium at a density of 4x106 cells/well. SIM-A9 cells were grown in a FalconTM 
Cell Culture Insert (1 μm pore size, Cat#: C353104) in a separate plate at a density of 1 × 
106 cells/per insert in 200 μl of medium overnight at 37°C and 5% CO2, then treated with 
Bindarit (300 µM) or RS504393 (100 µM) for 12 hours. After that, the inserts containing 
SIM-A9 cells were placed into the wells containing the cortical neurons or cerebellar 
neurons. The co-cultures were then treated with ethanol for 48 hours. The viability of 
neurons was determined by a 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay as previously described [61] 
Immunoblotting 
After treatment, mice were anesthetized by intraperitoneal injection of 
ketamine/xylazine and the cerebral cortices and cerebella were immediately dissected. The 
tissue was frozen in liquid nitrogen and stored at -80°C. The protein from brain tissue or 
SIM-A9 cells were extracted and processed for immunoblotting (IB) as previously 
described [61]. Briefly, tissues or cells were homogenized in an ice cold lysis buffer 
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containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, 0.5% NP-40, 0.25% 
SDS, 1 mM PMSF, 5 μg/ml leupeptin, and 5 μg/ml aprotinin. Homogenates were 
centrifuged at 20,000 g for 30 min at 4°C and the supernatant fraction was collected. 
Aliquots of the protein samples were separated on a SDS-polyacrylamide gel by 
electrophoresis. The separated proteins were transferred to nitrocellulose membranes. The 
membranes were probed with primary antibodies overnight at 4°C. The immune complexes 
were detected by the enhanced chemiluminescence substrate (GE Healthcare, Chalfont, 
Buckinghamshire, UK). The density of immunoblotting was quantified with the software 
of Image lab 5.2 (Bio-Rad Laboratories, Hercules, CA).  
Immunohistochemistry and determination of activated microglia 
The procedure for immunohistochemistry (IHC) has been previously described 
[63]. Briefly, the pups were decapitated and the brain tissues were removed, post fixed in 
4% paraformaldehyde for 24 hours and then transferred to 30% sucrose in PBS until the 
brain sunk to the bottom. Sagittal brain sections (20-40 μm) were cut on a freezing 
microtome. Floating sections were permeabilized with 0.1% Triton X-100 in PBS and 
incubated in 0.3% H2O2/50% methanol in PBS and then mounted on slides and dried. The 
slides were blocked with 5% normal goat serum containing 0.5% Triton X-100 in PBS at 
room temperature, and then incubated with primary antibodies (diluted in PBS with 1% 
BSA) overnight at 4°C. The dilution for the primary antibodies was: anti-cleaved caspase-
3 antibody, 1:600; anti-Iba1 antibody, 1:600. After washing with PBS, slides were 
incubated with a biotin-conjugated goat anti-rabbit secondary antibody (1:1,000) for 1 hour 
at room temperature and then washed with PBS. Avidin-biotin-peroxidase complex was 
prepared according to the manufacturer's instructions. The slides were incubated in the 
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complex for 1 hour at room temperature. After rinsing, the slides were developed in 0.05% 
3, 3′-diaminobenzidine (DAB) containing 0.003% H2O2 in PBS. 
Activated microglia were determined morphologically using ImageJ. The resting 
microglia exhibit long branching processes and a small cellular body, while the activated 
microglia have fewer but thicker processes with a larger cell body [64]. The average 
numbers of activated, Iba-1 positive cells and all Iba-1 positive cells were calculated from 
three randomly selected microscopic fields, and three consecutive sections were analyzed 
for each brain. 
Statistical analysis 
The data were presented as mean ± SEM. Statistical significance was determined 
by the ANOVA followed by Tukey’s post-hoc test. Differences in which p was < 0.05 were 
considered statistically significant. 
 
Results 
Ethanol increases MCP-1 expression in the developing brain and cultured microglial 
cells  
Ethanol exposure increases the expression MCP-1 in the adult brain of mice and 
human alcoholics [22, 23]. To evaluate the role of MCP-1/CCR2 in ethanol-induced 
damage in the developing brain, we first sought to determine the effect of ethanol on MCP-
1/CCR2 expression in the developing brain. Using a well-established mouse model of 
postnatal ethanol exposure [2, 30, 46], we showed that ethanol increased MCP-1 expression 
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but not CCR2 in the brain of postnatal day 4 (PD4) mice (Fig. 2.2A). Ethanol also up-
regulated MCPIP, a down-stream effector of MCP-1/CCR2 signaling. Since microglia are 
the major source of MCP-1, we examined the effect of ethanol on a cultured microglial cell 
line (SIM-A9) and observed that ethanol drastically increased the expression of MCP-1 but 
not CCR2 in SIM-A9 cells (Fig. 2.2B).   
 
 
Fig. 2.2. Effect of ethanol on MCP-1 and CCR2 expression. A: C57BL6 mice of postnatal 
day 4 (PD4) were exposed to ethanol (EtOH) as described in the Materials and Methods. 
Eight hours after EtOH exposure, mice were sacrificed and the brain was processed for 
immunoblotting (IB) analysis of MCP-1 and CCR2. The expression of MCP-1, MCPIP 
and CCR2 in the brain was quantified and normalized to actin. Each data point was the 
mean ± SEM of six animals. B: SIM-A9 cells were exposed to EtOH (0.4%) for 3, 6, 12 or 
12 hours. The expression of MCP-1 and CCR2 was determined by IB, and quantified by 
the normalization to the expression of actin. Each data point was the mean ± SEM of three 





Bindarit and RS504393 block ethanol-induced caspase-3 activation in the developing 
brain 
In this model of postnatal ethanol exposure, ethanol caused a wide-spread 
neuroapoptosis in the developing brain, which was indicated by the expression of cleaved 
caspase-3 [2, 30, 46]. As shown in Fig. 2.3, a significant alteration in cleaved caspase-3 
was observed in the cortex, cerebellum. Ethanol increased the expression of cleaved 
caspase-3 in the cerebral cortex and cerebellum. Bindarit or RS504393 treatment 
significantly decreased ethanol-induced caspase-3 activation. There was little caspase-3 




Fig. 2.3. Effect of Bindarit and RS504393 on ethanol-induced apoptotic neuronal death in 
the developing mouse brain. Bindarit (100 mg/kg) or RS504393 (1 mg/kg) were 
administered by two subcutaneous (SC) injections at 24 and 0.5 hours prior to EtOH 
exposure as described in the Materials and Methods. Eight hours after EtOH injection, 
the pups were sacrificed and the brains were harvested. The expression of cleaved 
caspase-3 in the cerebral cortex (CTX) and cerebellum (CB) was determined by IB and 
quantified by the normalization to actin. Each data point was the mean ± SEM of six 
animals. *p < 0.05, statistically significant difference from control group; # p < 0.05, 






Bindarit and RS504393 alleviate ethanol-induced proinflammatory cytokines and 
microglial activation  
Ethanol-induced neuronal death is accompanied by neuroinflammation which may 
play a role in CNS damage. We sought to determine whether Bindarit or RS504393 can 
reduce ethanol-induced neuroinflammation. Interleukin-6 (IL-6) and tumor necrosis factor 
alpha (TNFα) are major pro-inflammatory cytokines that are involved in injuries in the 
CNS [65, 66]. Ethanol increased the expression of IL-6 and TNFα in the brain of PD4 mice 
and cultured SIM-A9 cells; Bindarit and RS504393 inhibited ethanol-induced increase of 
IL-6 and TNFα in the developing brain (Fig. 2.4A) and in cultured SIM-A9 cell (Fig. 2.4B).  
Pathological activation of microglia is involved in neuroinflammation and 
neurodegeneration in various CNS disorders [67-70]. We therefore examined the effect of 
Bindarit or RS504393 on ethanol-induced microglia activation. Microglial activation was 
assessed morphologically by IHC of Iba-1. Ethanol significantly increased the number of 
active microglia; Bindarit and RS504393 inhibited ethanol-induced activation of microglia  
(Fig. 2.5).  
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Fig. 2.4. Effect of Bindarit and RS504393 on ethanol-induced inflammation in the 
developing brain and SIM-A9 cells. A. Bindarit (100 mg/kg) or RS504393 (1 mg/kg) were 
administered by two subcutaneous (SC) injections at 24 and 0.5 hours prior to EtOH 
exposure as described in the Materials and Methods. Eight hours after EtOH injection, the 
pups were sacrificed and brains were harvested. The relative expression for 
proinflammatory cytokines IL-6 and TNFα in the brain of PD4 mice were determined with 
IB and quantified as described above. Data are the mean ± SEM of six independent animals. 
*p < 0.05, statistically significant difference from control group; #p < 0.05, statistically
significant difference from EtOH-treated group. B. SIM-A9 cells were pretreated with 
Bindarit (300 µM) or RS504393 (100 µM) for 12 hours prior to EtOH (0.4%) exposure. 
After ethanol exposure for 12 hours, cells were harvested and processed for the expression 
of proinflammatory IL-6 and TNFα by IB as described above. Data are the mean ± SEM 
of three independent experiments. *p < 0.05, statistically significant difference from 




Fig. 2.5. Effect of Bindarit and RS504393 on ethanol-induced microglial activation in the 
developing mouse brain. Bindarit (100 mg/kg) or RS504393 (1 mg/kg) were administered 
by two subcutaneous (SC) injections at 24 and 0.5 hours prior to EtOH exposure as 
described above. Eight hours after EtOH injection, the pups were sacrificed and brains 
were harvested. A representative image of inferior colliculus is shown. Microglia were 
identified by IHC of Iba-1. Resting and activated microglia were determined 
morphologically using ImageJ. The resting microglia exhibit long branching processes and 
a small cellular body, which indicated by an arrow head; while the activated microglia have 
fewer but thicker processes with a larger cell body, which is indicated by arrow. The 
percentage of activated Iba-1 positive cells in total Iba-1 positive cells was calculated as 
described in the Materials and Methods. Bar = 50 μm. Each data point was the mean ± 
SEM of three animals. *p < 0.05, statistically significant difference from control group, #p 
<0.05, statistically significant difference from EtOH-treated group. 
 
Bindarit and RS504393 protect neurons against ethanol-induced neuronal death in 
co-cultures of primary neurons and microglia cells 
Since inhibition of MCP-1/CCR2 signaling alleviated ethanol-induced 
neuroapoptosis and microglial activation in the developing brain, we hypothesized that 
MCP-1/CCR2-regulated microglial activation may contribute to neuronal death. To test 
this hypothesis, we used a co-culture system in which primary neurons (mouse cortical 
neurons or cerebellar neurons) and microglial cells (SIM-A9 cells) were cultured together, 
allowing communication without direct contact. As shown in Fig. 2.6A, ethanol- and MCP-
1-induced neuronal death was greater in microglia/neuron co-cultures than in cerebellar 
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neuron or cortical neuron cultures alone. Bindarit and RS504393 significantly ameliorated 
ethanol-induced neuronal death in the microglia/cerebellar neuron and microglia/cerebellar 




Fig. 2.6. Effect of Bindarit and RS504393 on ethanol-induced neuronal death in the co-
cultures of microglia/primary neurons. A. Co-cultures of SIM-A9 cells and primary cortical 
neurons/cerebellar neurons were established described in the “Methods” section. The co-
cultures were treated with MCP-1 (10 ng/ml in PBS) or EtOH (0.4%) for 48 h. The viability 
of neurons was determined by MTT as described in the “Methods” section. Data were the 
mean ± SEM of three independent experiments. *p < 0.05, statistically significant 
difference from primary neuronal culture alone. B. SIM-A9 cells were treated with Bindarit 
(300 μM) or RS504393 (100 μM) for 12 h. After that, the inserts containing SIM-A9 cells 
were placed in the culture wells containing cortical neurons or cerebellar neurons. The co-
cultures were then treated with EtOH (0.4%) for 48 h, and the viability of neurons was 
determined by MTT. Each data point was the mean ± SEM of three independent 
experiments. *p < 0.05, statistically significant difference from co-cultures without 
Bindarit or RS504393 treatment. 
 
TLR4 and GSK3β mediate ethanol-induced proinflammatory cytokines in microglial 
cells 
It is well established that TLR4 and its downstream adaptors TRIF and MyD88 
regulate microglial activation and production of inflammatory mediators [71-73]. GSK3β 
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is also a key mediator of microglial activation and neuroinflammation [74-76]. MCP-1 was 
shown to activate GSK3β signaling in human breast carcinoma cells [77]. We hypothesized 
that the interaction among MCP-1/CCR2, TLR4, and GSK3β may mediate ethanol-induced 
microglial activation and expression of proinflammatory factors.  We first determined 
whether TLR4 and GSK3β were involved in ethanol-induced expression of 
proinflammatory cytokines. We pre-treated SIM-A9 cells with either TLR4 inhibitor 
TAK242 or GSK3β inhibitor SB216763 to block TLR4 and GSK3β signaling prior to 
ethanol exposure. As shown in Fig. 2.7. TAK242 and SB216763 drastically attenuated 
ethanol-induced increase in the expression of Iba-1, IL-6, and TNF-α. We next sought to 
determine whether MCP-1/CCR2 signaling was involved in ethanol-activated GSK3β and 
TLR4. The activity of GSK3β is mainly regulated by the phosphorylation at serine 9 which 
results in the inhibition of GSK3β [78-80], conversely, the phosphorylation at tyrosine 216 
positively regulated its activity [81]. As shown in Fig 2.8A, ethanol activated GSK3β by 
reducing the phosphorylation at Ser9 in SIM-A9 cells; blocking MCP-1/CCR2 signaling 
by Bindarit or RS504393 attenuated ethanol-induced dephosphorylation of GSK3β (Ser9). 
Blocking MCP-1/CCR2 signaling also inhibited ethanol-induced TLR4. Animal studies 
confirmed these findings and showed that Bindarit or RS504393 treatment attenuated 
ethanol-induced dephosphorylation of GSK3β (Ser9) and upregulation of TLR4, MyD88 
and, TRIF in the brain of PD4 mice (Fig. 2.8B). 
We then investigated the interaction between TLR4 and GSK3β in response to 
ethanol exposure. Inhibition of TLR4 signaling by TAK242 attenuated ethanol-induced 
dephosphorylation of GSK3β (Ser9) and upregulation of MCP-1 in SIM-A9 cells (Fig. 
2.8C); while blocking GSK3β activation by SB216763 inhibited ethanol-induced 
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upregulation of MCP-1 and TLR4 (Fig. 2.8D). The results indicated that there was 
considerable interaction among MCP-1/CCR2 signaling, TLR4, and GSK3β in response to 
ethanol exposure.   
Fig. 2.7. Role of TLR4 and GSK3β in EtOH-induced inflammation. SIM-A9 cells were 
pretreated with TAK242 (1 µM) or SB-216763 (10 µM) for 12 hours, then exposed to 
EtOH (0.4%) for 12 hours. The expression of Iba-1, TNFα and IL-6 was determined by IB, 
and quantified by the normalization to the expression of actin. Each data point the mean ± 
SEM of three independent experiments. *p < 0.05, statistically significant difference from 










Fig. 2.8. The interaction of MCP-1/CCR2 signaling, TLR4 and GSK3β in response to 
ethanol exposure. A. SIM-A9 cells were pretreated with RS504393 (100 µM) or Bindarit 
(300 µM) for 12 hours, and then exposed to EtOH (0.4%) for 12 hours. The expression of 
GSK3β, phosphorylated GSK3β at serine 9 (phospho-GSK3βS9), phosphorylated GSK3β 
at tyrosine 216 (phospho-GSK3βY216), and TLR4 were determined by IB and quantified by 
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the normalization to the expression of actin. B. C57BL6 mice of PD4 were treated with 
Bindarit, RS504393 and EtOH as described in Fig. 1.2. Eight hours after EtOH treatment, 
the expression of TLR4 and its downstream adaptors TRIF and MyD88, and  phospho-
GSK3βS9 in the brain was determined by IB and quantified by the normalization to the 
expression of actin. C. SIM-A9 cells were pretreated with TAK242 (1 µM) for 12 hours, 
and then exposed to EtOH (0.4%) for 12 hours. The expression of GSK3β, phospho-
GSK3βS9, phospho-GSK3βY216, MCP-1 and CCR2 was by IB and quantified by the 
normalization to the expression of actin. D. SIM-A9 cells were pretreated SB-216763 (10 
µM) for 12 hours, and then exposed to EtOH (0.4%) for 12 hours. The expression of TLR4, 
MCP-1 and CCR2 was by IB and quantified by the normalization to the expression of actin. 
Each data point was the mean ± SEM of three independent experiments. *p < 0.05, 
statistically significant difference from control group; #p < 0.05, statistically significant 
difference from EtOH-treated group. 
 
Based on these findings, we propose a model to illustrate the cascade of ethanol-
induced microglial activation and neuroinflammation (Fig. 2.9). In this model, ethanol 
could directly or indirectly activate TLR4, and stimulate its down-stream effectors such as 
TRIF and MyD88; the active TLR4 may also activate GSK3β which may further stimulate 
TLR4. As a result, the activation of TRIF, MyD88, and GSK3β stimulates transcription 
factors, such as AP-1 and NF-κB which upregulate the expression of proinflammatory 
cytokines and chemokines (e.g. TNF-α, IL6, and MCP-1). The released MCP-1 interacts 
with CCR2 and further activates GSK3β and TLR4; the positive feedback loop intensifies 
the neuroinflammation toxic to neurons. It is also possible that ethanol could directly 
activate CCR2 and initiate the down-stream signaling cascades. This possibility is worthy 





Fig. 2.9. The interaction among MCP-1/CCR2 signaling, TLR4, GSK3β in ethanol-
induced neuroinflammation. EtOH may stimulate TLR4 and possibly CCR2, and activate 
the downstream effectors, such as TRIF and MyD88.  Active TLR4 may also activate 
GSK3β which may further stimulate the TLR4 pathway. As a result, the activation of TRIF, 
MyD88, and GSK3β stimulates transcription factors which upregulate the expression of 
proinflammatory cytokines and chemokines (e.g. TNF-α, IL6, and MCP-1). The released 
MCP-1 interacts with CCR2 and further activates TLR4 and GSK3β; the positive feedback 
loop intensifies the neuroinflammation that is toxic to neurons in the developing CNS.  
 
Discussion 
In this study, we showed that ethanol increased the expression of MCP-1 but not 
CCR2 in the brain of PD4 mice and microglia cells (SIM-A9). The MCP-1 synthesis 
inhibitor Bindarit and CCR2 antagonist RS504393 inhibited ethanol-induced 
neuroapoptosis, microglial activation, and the expression of pro-inflammatory factors. 
Further studies using gene knock out mice confirmed that the deficiency in MCP-1 or 
CCR2 made mice more resistant to ethanol-induced neurodegeneration. Moreover, ethanol 
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and MCP-1 caused more neuronal death in neuron/microglia co-cultures than neuronal 
culture alone. Blocking MCP-1/CCR2 signaling protected primary cortical and cerebellar 
neurons against ethanol-induced death in the neuron/microglia co-cultures. It appeared that 
TLR4 and GSK3β mediated ethanol-induced microglial activation and production of pro-
inflammatory cytokines in cultured microglia cells, and there was considerable interaction 
among TLR4, GSK3β, and MCP-1/CCR2 signaling in response to ethanol exposure.  
The mechanisms underlying ethanol-induced neurodegeneration in the developing 
brain are complex. Multiple mechanisms may be involved; these include oxidative stress 
[3, 4], endoplasmic reticulum (ER) stress [2] and interference of signaling by neurotrophic 
factors and disruption of microRNAs [5]. Recent evidence indicates that 
neuroinflammation plays an important role in the pathogenesis of FASD and AUD [6-8]. 
Ethanol-induced neurodegeneration in both adult and developing brain is accompanied by 
microglial activation and neuroinflammation [6, 7, 9, 10]. We have recently shown that 
inhibition of microglial activation and neuroinflammation by minocycline offered 
protection against ethanol-induced neurodegeneration in the developing brain [62], 
suggesting that microglial activation and neuroinflammation may contribute to ethanol 
neurotoxicity in the immature CNS.  
MCP-1 is a key chemokine involved in neuroinflammation. In mouse and human 
brain, MCP-1 and its receptor CCR2 are primarily expressed by microglia [11]. MCP-
1/CCR2 signaling is involved in numerous neuroinflammatory diseases, such as multiple 
sclerosis, stroke and Alzheimer’s [14-19]. Chronic ethanol exposure induces MCP-1 
expression in adult human and mouse brain [24, 25]. We have recently shown that ethanol 
stimulated MCP-1/CCR-2 signaling in the spinal cord of early postnatal mice, and 
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knocking out MCP-1 or CCR2 made mice resistant to ethanol-induced apoptosis of spinal 
cord neurons [26], indicating the involvement of MCP-1/CCR2 signaling in ethanol-
induced neurodegeneration in the developing spinal cord.  
The current study showed that ethanol upregulated MCP-1 at both mRNA and 
protein levels but not CCR2 expression in the developing brain. Ethanol stimulation of 
MCP-1/CCR2 signaling was confirmed by an up-regulation of the down-stream effector, 
MCPIP. Disrupting MCP-1/CCR2 signaling by either MCP-1 synthesis inhibitor or CCR2 
antagonist made mice less susceptible to ethanol-induced apoptotic cell death, microglial 
activation and the expression of pro-inflammatory factors. MCP-1/CCR2 signaling plays 
an important role in microglial activation and neuroinflammation [11-13, 82]. Therefore, 
the neuroprotection caused by the disruption of MCP-1/CCR2 signaling may result from 
suppression of microglial activation and neuroinflammation. Using a neuron/microglia co-
culture system, we demonstrated that the presence of microglial cells indeed exacerbated 
ethanol-induced neuronal death; while blocking MCP-1/CCR2 signaling attenuated 
enhanced ethanol neurotoxicity in this neuron/microglia co-culture system. The result 
further supported the hypothesis that the activation of microglia contributed to ethanol 
neurotoxicity. Although our findings suggest that MCP-1/CCR2-mediated microglial 
activation and neuroinflammation is involved in ethanol neurotoxicity, we could not rule 
out the possibility of ethanol directly killing the neurons. In primary neuronal cultures 
alone, ethanol also reduced neuronal viability but to a lesser extent, compared to 
neuron/microglia co-cultures. It is possible that in the brain ethanol initially causes 
neuronal damage, triggering MCP-1/CCR2-mediated microglial activation and 
neuroinflammation, which further exacerbates neurodegeneration.  
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Although MCP-1 and CCR2 are primarily expressed by microglia in mouse and 
human brain, they are also expressed in other cell types in the brain, such as astrocytes and 
neurons, but to a lesser extent [11, 83, 84]. Therefore, the situation in vivo is  complex and 
it is difficult to separate the effects of microglia-derived MCP-1 from that deprived from 
other cell types unless microglia-specific MCP-1 or CCR2 knock out mice are available.  
TLR4, GSK3β and p38 MAPK are important regulators of microglial activation 
and neuroinflammation [71, 73, 85-87]. Since ethanol had little effect on p38 MAPK in the 
developing brain [62], we focused on TLR4 and GSK3β in this study.  Indeed, TLR4 and 
GSK3β were activated by ethanol and involved in ethanol-induced microglial activation 
and up-regulation of proinflammatory cytokines. Ethanol activated GSK3β by inducing 
dephosphorylation of GSK3β at Ser9 in vitro and in vivo. This is consistent with our 
previous findings that ethanol decreased the phosphorylation of GSK3β (Ser9) in the 
developing brain and cultured neuronal cells [79, 88]. Blocking MCP-1/CCR2 signaling 
partially mitigated ethanol-induced dephosphorylation of GSK3β (Ser9), therefore 
alleviating ethanol-mediated activation of GSK3β. Similarly, blocking MCP-1/CCR2 
signaling effectively inhibited ethanol-induced up-regulation of TLR4 in vitro and in vivo. 
These results suggest that MCP-1/CCR2 signaling was involved in ethanol-induced 
activation of GSK3β and TLR4.  
It appears that there was considerable interaction among MCP-1/CCR2 signaling, 
GSK3β, and TLR4 in response to ethanol exposure. Blocking TLR4 by TAK242 alleviated 
ethanol-induced dephosphorylation of GSK3β (Ser9) and partially inhibited ethanol-
induced up-regulation of MCP-1. On the other hand, blocking GSK3β also attenuated 
ethanol-induced up-regulation of MCP-1 and TLR4. Based on these findings, we propose 
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a model to illustrate the cascade of ethanol-induced microglial activation and 
neuroinflammation. In this model, ethanol could directly or indirectly activate TLR4, and 
stimulate its down-stream effectors such as TRIF and MyD88; the active TLR4 may also 
activate GSK3β which may further stimulate TLR4. As a result, the activation of TRIF, 
MyD88, and GSK3β stimulates transcription factors, such as AP-1 and NF-κB which 
upregulate the expression of proinflammatory cytokines and chemokines (e.g. TNF-α, IL6, 
and MCP-1). The released MCP-1 interacts with CCR2 and further activates GSK3β and 
TLR4; the positive feedback loop intensifies the neuroinflammation toxic to neurons. It is 
also possible that ethanol could directly activate CCR2 and initiate the down-stream 














CHAPTER 3: ROLE OF MCP-1/CCR2 IN BEHAVIOR DEFICIT INDUCED BY 
NEONATAL ALCOHOL EXPOSURE 
Synopsis 
Background: Alcohol exposure during the development causes profound long term 
physical and neurocognitive deficits. In chapter 2, we showed that MCP-1/CCR2 
signaling was involved in alcohol-induced neuroninflammation and neurodegeneration in 
the developing central nervous system (CNS); inhibition of MCP-1/CCR2 signaling 
reduced alcohol-induced neuronal death. In this study, we sought to determine whether 
knock out of MCP-/CCR2 ameliorates neonatal alcohol exposure-induced behavioral 
deficits.  
Methods: C57BL/6 and MCP-1/CCR2 deficient (MCP-1-/-/CCR2-/-) mice were exposed to 
alcohol (5 g/kg) by subcutaneous injection on postnatal days (PD) 4. A series of behavioral 
tests including Open Field, Rotor-Rod, Balance Beam, and Morris Water Maze (MWM) 
were performed in the adolescence and adulthood.  
Results: Compared to wild-type mice, MCP-1-/-/CCR2-/- mice were more resistant to 
neonatal alcohol exposure-induced deficits in general motor function and coordination 
which were determined by Rotor-Rod testing and Balance Beam testing. MCP-1 and CCR2 
deficiency also protected mice against neonatal alcohol exposure- induced long lasting 
deficits in learning and memory which was determined by MWM. 
Conclusion: MCP-1/CCR2 signaling played an important role in ethanol-induced long-
lasting behavioral deficits in the developing brain. 
Keywords:  





Alcohol consumption during pregnancy causes fetal alcohol spectrum disorders 
(FASD), leading to deficits in learning, memory, motor function, visual-spatial ability and 
executive function [89-92]. Alcohol-induced neurobehavioral deficits have been replicated 
in rodent models of FASD using either prenatal or neonatal alcohol exposure [93-98]. The 
behavioral deficits associated with FASD are due, in large part, to alcohol-induced 
neuronal losses in the developing CNS. Although the mechanisms underlying alcohol-
induced neuronal death in the developing CNS remain unclear, it is believed that 
neuroinflammation and neurodegeneration play an important role [26, 99, 100]. In both the 
developing and adult brain, alcohol-induced neuronal death is accompanied by microglial 
activation and neuroinflammation [6, 7, 9, 10]. Some studies show that targeting microglial 
activation and neuroinflammation is able to ameliorate alcohol-induced neuronal death in 
vitro and in vivo [99-102]. However, few studies investigate the impact of targeting 
microglial activation and neuroinflammation on neurobehavioral outcomes in the context 
of developmental exposure to alcohol.  
MCP-1, also called chemokine (CC motif) ligand 2 (CCL2), is a key chemokine 
involved in the regulation of neuroinflammation [11-13]. In mouse and human brain, MCP-
1 and its receptor C-C chemokine receptor type 2 (CCR2) are primarily expressed by 
microglia [11]; they are also expressed in astrocytes and neurons but to a lesser extent [14]. 
Using a third trimester equivalent mouse model of alcohol exposure, we previously 
demonstrated that MCP-1 or CCR2 deficient mice were resistant to alcohol-induced 
apoptosis, inflammation, and glial activation in the developing spinal cord and brain [26]. 
Furthermore, treatment of MCP-1 synthesis inhibitor Bindarit or CCR2 antagonist 
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RS504393 significantly inhibited alcohol-induced microglial activation, 
neuroinflammation and neuroapoptosis in the brain of early postnatal mouse pups [99]. 
Together, these results suggest that MCP-1/CCR2 signaling plays an important role in 
alcohol neuroinflammation and neuronal death in the developing CNS. In this study, we 
sought to determine whether knock out of MCP-1 and CCR2 ameliorates neonatal alcohol 
exposure-induced behavioral deficits. To effectively block MCP-1/CCR2 signaling in 
mice, we generated a double knock out mouse strain which is deficient of both MCP-1 and 
CCR2 (MCP-1-/-/CCR2-/-). We showed that MCP-1-/-/CCR2-/- mice were more resistant to 
neonatal alcohol exposure-induced deficits in motor function, and learning and memory in 




Materials and Methods 
Reagents  
Anti-MCP-1 antibody was purchased from Bio-Rad AbD Serotec, Inc. (Raleigh, 
NC, USA). Anti-CCR-2 antibody was purchased from BioVision, Inc. (Milpitas, CA, 
USA).  PCR primers were purchased from Invitrogen (Carlsbad, CA, USA). PCR 
genotyping master mix was purchased from EZ Bioresearch (St. Louis, MO, USA).   
 
Animals and alcohol exposure 
C57BL/6J, MCP-1−/− (B6.129S4-Ccl2tm1Rol/J) and CCR2−/− (B6.129S4-
Ccr2tm1Ifc/J) mice were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). 
Mice were maintained in the Division of Laboratory Animal Resources of the University 
of Kentucky Medical Center. All procedures were performed in accordance with the 
guidelines set by the National Institutes of Health (NIH) Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Kentucky (Account #: 2008-0401). Animals 
were maintained in a 12 /12 hours light/dark cycle with a temperature of 22±1°C and 
relative humidity of 60±5%, and received standard chow and water ad libitum. MCP-1-/-
/CCR2-/- double knockout line (KO) was produced by crossing MCP-1−/− mice with 
CCR2−/− mice. The deletion of MCP-1 and CCR2 was confirmed by genotyping and 
immunoblotting. Both male and female mice were used in the study. A quick, easy and 
reliable 'spot on' method was used to determine the sex of the new born mice [103]. 
We used a well-established third trimester equivalent mouse model of alcohol exposure 
in which alcohol produces wide spread neurodegeneration in the developing brain [46, 
99]. Pups from both C57BL/6J mice and MCP-1-/-/CCR2-/- KO mice were weighed on 
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PD4. The C57BL/6J pups and KO pups received a total of 5 g/kg ethanol  or equal 
volume of saline as control in two subcutaneous (SC) injections which were two hours 
apart; each contained ethanol (2.5 g/kg, 20% solution in saline) [2, 46]. We have 
previously determined that the blood alcohol concentration (BAC) was 338 mg/dL 8 
hours after the first injection [2]. High BAC was observed among women of childbearing 
age [47, 49, 50]. Some alcoholics with a BAC > 400 mg/dL were coherent and able to 
drive [50]. To eliminate effects from the adolescent behavioral tests, we used a different 
set of mice for the adolescent and adult behavioral tests. There were four groups of mice 
for each of the behavioral tests: Control (C57BL/6J, saline), KO (MCP-1-/-/CCR2-/-, 
saline), Ethanol (C57BL/6J, ethanol), and KO + Ethanol (MCP-1-/-/CCR2-/-, ethanol). 
Male and female mice were analyzed separately. There were 16 animals (8 male and 8 
female) for each treatment group. The time line of alcohol exposure and behavioral tests 
is shown in Fig. 3.1
 
Fig. 3.1: Timeline of alcohol exposure and behavioral tests. (A) Timeline of alcohol 
exposure and adolescent behavioral tests. Mouse pups received two subcutaneous (SC) 
injections of ethanol which were two hours apart on PD4; each contained ethanol (2.5 g/kg, 
20% ethanol in saline). Open Field test was performed on PD35-36; Rotor-Rod test was 
performed on PD38; Balance Beam was performed on PD40; Morris Water Maze was 
performed on PD42-46. (B) Timeline of alcohol exposure and adult behavioral tests. 
Mouse pups received two subcutaneous (SC) injections of ethanol which were two hours 
apart on PD4; each contained ethanol (2.5 g/kg, 20% ethanol in saline). Open Field test 
was performed on PD70-71; Rotor-Rod test was performed on PD73; Balance Beam was 





The genotyping for MCP-1 and CCR2 was performed based on the genotyping 
protocols provided by the Jackson Laboratory (#004434 and #004999). Briefly, on PD 21, 
2 mm of the tail was cut and placed into an Eppendorf tube containing 75 uL of 25 mM 
NaOH and 0.2 mM EDTA. After incubation in a thermocycler at 98°C for 1 h, 75 uL of 40 
mM Tris HCl (pH 5.5) was added to the tube. An aliquot (2 uL of a 1:100 dilution/reaction) 
was used for PCR after centrifugation at 4000 rpm for 3 min. The primers used for the 
MCP-1 PCR are oIMR7415, oIMR9219 and oIMR9220 (Jackson Laboratory #004434), 
the primers used for the CCR2 PCR are 26367, oIMR3375 and oIMR6218 (Jackson 
Laboratory #004999). DNA samples were resolved in 2% agarose gel.   
 
Immunoblotting 
MCP-1/CCR2 immunoblotting was used for the confirmation of the deletion of 
MCP-1 and CCR2 in addition to genotyping. Eight hours after alcohol exposure on PD4, 
mice were anesthetized by intraperitoneal injection of ketamine/ (100 mg/kg)/xylazine (10 
mg/kg) and the whole brain were immediately dissected. The tissue was frozen in liquid 
nitrogen and stored at -80°C. The protein from brain tissue were extracted and processed 
for immunoblotting (IB) as previously described [99]. Briefly, tissues were homogenized 
in ice cold lysis buffer containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, 
0.5% NP-40, 0.25% SDS, 1 mM PMSF, 5 μg/mL leupeptin, and 5 μg/mL aprotinin. 
Homogenates were centrifuged at 20,000 g for 30 min at 4°C and the supernatant fraction 
was collected. Aliquots of the protein samples were separated on a SDS-polyacrylamide 
gel by electrophoresis. The separated proteins were transferred to nitrocellulose 
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membranes. The membranes were probed with primary antibodies overnight at 4°C. The 
immune complexes were detected by the enhanced chemiluminescence substrate (GE 
Healthcare, Chalfont, Buckinghamshire, UK). The density of immunoblotting was 
quantified with the software of Image lab 5.2 (Bio-Rad Laboratories, Hercules, CA).  
 
Behavioral tests 
All the behavioral tests (Open Field, Rotor-Rod, Balance Beam and Morris Water 
Maze were performed at the Rodent Behavior Core (RBC) at University of Kentucky.  
Open Field test: The Open Field test is commonly used to assess ability to cope with the 
stress‐inducing aspects of a novel environment [104-106]. Activities in the center were 
used to evaluate anxiety-related behaviors as mice typically display thigmotaxis and avoid 
the center of open arenas [105]. The arena was a 50 x 50 cm square box with raised walls 
of 50 cm. The center was defined as a 25 x 25 cm square zone in the center of the open 
field. Animals were tested for 15 min daily for two days (PD35-36 or PD70-71). The 
distance travelled in the center, and the time spent in the center and in the whole arena were 
recorded by EthoVision XT (Noldus Information Technology, The Netherlands). The 
center/total duration (%) was calculated from the time spent in the center/the total time 
spent in the arena x 100%.   
 
Rotor Rod test: The Rotor Rod test is a well-characterized test of gross motor function 
[107]. The Rotor-Rod test consists of a rotating beam, on which mice are required to walk. 
Mice were tested on PD38 or PD73. Before testing session began, mice were given a 
training session in order to familiarize them with the procedure. They were trained to grip 
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the rod by being placed on the rod rotating at the lowest speed (4 rpm) for a total of 60 s 
regardless of the number of falls. There were three testing sessions; in each testing session, 
a mouse was placed on the rod facing opposite to the direction of rotation and was allowed 
to ambulate until it fell from the rod or the maximum observation time (300 s) had elapsed. 
The Rotor Rod for the testing session started at 4 rpm and slowly accelerated to 40 rpm, so 
that the longer the mouse remained on the rod, the faster it had to move to maintain balance. 
Mice were remained in cages for a 10 min intertrial interval (ITI) between each session. 
Every mouse underwent three testing sessions. The performance on the rod was quantified 
by the fall latency and distance traveled, which were recorded with ROTOR-ROD™ 
System (San Diego Instruments, Inc., San Diego, CA, USA). The latency and distance of 
each mouse was calculated from three trials (mean ± SEM).   
 
Balance Beam test: The Balance Beam test has been widely used for assessing fine motor 
balance and coordination and detecting subtle motor function deficits that may not be 
revealed in Rotor-Rod testing [108]. The beam consisted of an 80 cm horizontal wood bar 
(0.5 or 1 cm in width) connected with a safe house on one end of the bar. The bar and the 
safe house were placed 14 cm above the floor. On PD40 or PD75, following the habituation 
trials, the mice were placed at the starting point of the beam. The performance on the beam 
was quantified by measuring the time it takes for the mouse to traverse the beam and the 
number of foot slips that occur in the process (recorded by counter and stopwatch). The 




Morris water maze (MWM): The MWM is a well-validated test for spatial learning and 
memory [109]. MWM is an open circular pool (diameter 121.92 cm) that is filled with 
water (22-25°C). A platform (10.2 × 10.2 cm) is submerged 1 cm under the surface of the 
water in a fixed location (in the middle of the northeast quadrant). Enough white non-toxic 
water-based paint is added to the pool so that the pool is opaque and the platform is no 
longer visible. Four visible extramazal cues are located on the black curtain around the 
maze to assist the mice to find the hidden platform. Each mouse was placed in the pool 
from one of the four drop-off locations (north, south, east and west) between trails and 
allowed to swim until they found the platform, with a maximal time limit of 60 seconds. 
If the mouse finds the platform, it is remained on the platform for 15 s before being 
removed for a five-minute inter-trial interval; if it does not find the platform within the set 
time, the computer stopped tracking and recorded the time as 60 s, and the mouse is 
gently guided to the platform and remained there for 15 s. Twenty acquisition trials were 
administered for each mouse (four trials per day separated by a 5-min inter-trial interval, 
continued for 5 days). Mice were tested on PD42-46 or PD77-81. The performance was 
quantified by goal latency and path length to reach the platform. The swimming velocity 
of the fifth (last) day was also quantified to evaluate whether the goal latency was affected 
by swimming velocity. All the parameters were recorded with Ethovision XT (Noldus 
Information Technology, The Netherlands). The average goal latency, path length and 
swimming velocity for each mouse in one specific testing day was calculated from the four 
trials in that day.  
Statistical analyses 
Statistical analyses were conducted using Prism software. The data were presented 
as mean ± SEM. Statistical significance was determined by the ANOVA followed by 
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Tukey’s post-hoc test. Differences in which p was < 0.05 were considered statistically 
significant. We are also collaborating with Dr. Bin Huang, a biostatistician to use more 
advanced statistical tools to investigate: (1) whether male and female mice are differently 
affected by alcohol? (2) Is the protective effect of MCP-1/CCR2 deficiency different 
between male and female mice? (3) Whether adolescent and adult mice are differently 
affected by alcohol? (4) Is the protective effect of MCP-1/CCR2 deficiency different 
between adolescent and adult mice? These results will be available soon.  
Results 
 
Effects of neonate alcohol exposure on body weight 
First, we used PCR and immunoblotting to confirm the deletion of both MCP-1 and 
CCR2 in the mice.  A ~180 bp fragment resulted from a small deletion and an in frame 
stop codon created in exon 1 and a PGK-neomycin resistance cassette inserted into exon 2 
in MCP-1  and a ~390 bp fragment resulted from the replacement of the coding region and 
3' untranslated region with the polII-neo cassette in CCR2 were detected in the DNA 
samples of MCP-1-/-/CCR2-/- mice.  A ~290 bp fragment (full length MCP-1) and a ~490 
bp fragment (full length CCR2) were identified in the DNA samples of WT mice (Fig. 
3.2A). These results are consistent with the genetic information of the MCP-1-/- mice and 
CCR2-/- mice provided by the Jackson Laboratory (#004434 and #0049999). The results 
were further confirmed by using immunoblotting analysis. MCP-1 and CCR2 protein 
expression were only detected in the brain of wild type mice but not in the KO mice on 
PD4 (Fig. 3.2B). The result also replicated our previous findings that alcohol increased 
MCP-1 expression in the brain of PD4 mice [99]. Together, these results confirmed the 
deletion of both MCP-1 and CCR2 in the mice.  
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 The body weight was recorded on the day of alcohol administration (PD4) and the 
first day for each behavioral test (Table 1). Neonatal alcohol exposure significantly 
decreased the body weight of both wild type and MCP-1-/-/CCR2-/- mice which were 
measured at the adolescence and adulthood. Both male and female mice were similarly 
affected.  
 
Fig. 3.2. Confirmation of MCP-1/CCR2 deficiency. (A) On PD 21, 2 mm of the tail was 
cut and used for PCR analysis as described in the Materials and Methods. PCR analysis 
identified a ~290 bp and a ~490 bp fragment in the DNA samples from the WT mice and 
identified a ~180 bp and a ~390 bp fragment in the DNA samples from the double KO 
mice. These results are consistent with the genetic information of the MCP-1-/- mice and 
CCR2-/- mice from The Jackson Laboratory. (B) Eight hours after alcohol exposure on 
PD4, mice were sacrificed and whole brains were harvested and processed for 
immunoblotting analysis as described in the Materials and Methods. The same amount of 
protein from each mouse (three mice for one treatment group) were pooled in a group for 
the immunoblotting analysis. 
Table 3.1: Body Weight 
 
Table 3.1: The body weight was recorded on the day of alcohol administration (PD4) and 
the first day for each behavioral test. Each data point was the mean ± SEM of eight animals, 
#  indicates a significant difference from the controls, p < 0.05. 
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Neonatal alcohol exposure or MCP-1/CCR2 deficiency does not affect anxiety-related 
behavior of adolescent and adult mice  
In the Open Field testing, the distance travelled in the center and the center/total 
duration (%) were comparable among all groups (Fig. 3.3), which indicates that neonatal 
alcohol exposure or MCP-1/CCR2 deficiency did not affect anxiety-related behavior in 





Fig. 3.3. Effect of neonatal alcohol exposure on anxiety-related behavior in wild type 
and MCP-1/CCR2 knock out mice (MCP-1-/-/CCR2-/-, KO). Both male and female mice 
were exposed to alcohol (EtOH) on PD4 as described in the Materials and Methods. 
The Open Field tests were performed On PD35-36 or PD70-71. The distance for each 
mouse travelled in the center of the arena was measured for two days (Fig. A for 
adolescent male, Fig. C for adolescent female, Fig. E for adult male, Fig. G for adult 
female). The time for each mouse spent in the center and in the whole arena was also 
determined. The center/total duration (%) was calculated from the time spent in the 
center/the total time spent in the arena x 100% (Fig. B adolescent male, Fig. D for 
adolescent female, Fig. F for adult male, Fig. H for adult female). Each data point was 
the mean ± SEM of eight animals. 
MCP-1-/-/CCR2-/- mice are resistant to neonatal alcohol exposure-induced deficits in 
general motor function.  
A significant alteration in latency was observed in Rotor-Rod testing in adolescent 
male mice [F(3,92) = 21.26, p < 0.05], adolescent female mice [F(3,92)= 19.33, p < 0.05], 
adult male mice [F(3,92) = 22.03, p < 0.05] and adult female mice [F(3,92) = 20.15, p < 
0.05]. There was also a significant change in distance in adolescent male mice [F(3,92) = 
19.62, p < 0.05], adolescent female mice [F(3,92) = 18.17, p < 0.05], adult male mice 
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[F(3,92) = 23.85, p < 0.05] and adult female mice [F(3,92) = 20.21, p < 0.05]. The EtOH 
group fell off the rod significantly sooner and travelled significantly less than controls 
(p < 0.05); the KO + EtOH group showed a significant improvement in performance 
compared to EtOH group in both adolescence (Fig. 3.4A, B, C, D) and adulthood (Fig. 
3.4E, F, G, H). There was no significant difference in either latency or distance between 
control group and KO group. These results indicate MCP-1 and CCR2 deficiency protect 
mice against neonatal alcohol exposure-induced long lasting deficits in general motor 






Fig 3.4. Effect of neonatal alcohol exposure on general motor function in wild type and 
MCP-1/CCR2 KO mice. Both male and female mice were exposed to alcohol (EtOH) 
on PD4 as described in the Materials and Methods. The general motor function was 
assessed by Rotor Rod test on PD38 or PD73. The performance on the rod was 
quantified by the fall latency (Fig. A for adolescent male, Fig. C for adolescent female, 
Fig. E for adult male, Fig. G for adult female) and distance (Fig. B adolescent male, Fig. 
D for adolescent female, Fig. F for adult male, Fig. H for adult female) traveled as 
described in the Materials and Methods. The latency and distance for each mouse 
traveled on the rod was calculated from three trials, each data point was the mean ± 
SEM of eight animals. #  indicates a significant difference from the controls, p < 0.05. * 
indicates a significant difference from the Ethanol-treated group, p < 0.05 
 
MCP-1 and CCR2 deletion protects mice against neonatal alcohol exposure- induced 
long lasting deficits in motor coordination and balance 
The protective effect of MCP-1 and CCR2 dletion against neonatal alcohol 
exposure-induced long lasting deficits in motor function was further confirmed by using 
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the Balance Beam testing. Balance Beam testing has been widely used for assessing fine 
motor balance and coordination and detecting subtle motor function deficits that may not 
be revealed in Rotor-Rod testing [108]. One-way ANOVA revealed significant alterations 
in the time for traversing the beams for adolescent male mice [1 cm beam, F(3,92) = 9.18, 
p < 0.05; 0.5 cm beam, F(3,92) = 18.22, p < 0.05] and female mice [1 cm beam, F(3,92) = 
8.19, p < 0.05; 0.5 cm beam, F(3,92) = 17.69, p < 0.05]. Similarly, we observed significant 
alterations in the time for traversing the beams for adult male mice [1 cm beam, F(3,92) = 
10.02, p < 0.05; 0.5cm beam, F(3,92) = 16.73, p< 0.05] and adult female mice [1 cm beam, 
F(3,92)= 9.28, p < 0.05; 0.5cm beam, F(3,92) = 15.26, p < 0.05]. A significant alteration 
in the number of foot slips was also observed in adolescent male mice [1 cm beam, F(3,92) 
= 5.29, p < 0.05; 0.5 cm beam, F(3,92) = 13.02, p < 0.05] and adolescent female mice [1 
cm beam, F(3,92) = 6.19, p < 0.05; 0.5cm beam, F(3,92) = 13.76, p < 0.05]. A similar 
significant alteration was also observed in the number of foot slips in adult male mice [1 
cm beam, F(3,92) = 4.92, p < 0.05; 0.5 cm beam, F(3,92) = 11.83, p < 0.05] and adult 
female mice [1 cm beam, F(3,92) = 8.98, p < 0.05; 0.5 cm beam, F(3,92) = 17.34, p < 0.05]. 
The EtOH group spent significantly longer time on traversing the beams and 
had significantly more foot slips than controls (p < 0.05); the KO + EtOH group showed 
a significant improvement in performance compared to EtOH group in female mice (Fig. 
3.5C, D, G, H). There was also significantly fewer foot slips in the KO + EtOH group 
compared to EtOH group in adolescent and adult male mice (Fig. 3.5 B and F). There was 
no significant difference in time between KO + EtOH group and EtOH group in male mice 
(Fig 3.5A and E). There was also no significant difference in either time or number of foot 
slips between control group and KO group. These results indicated that MCP-1 and CCR2 
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deletion protected mice against neonatal alcohol exposure-induced long lasting deficits in 
motor coordination and balance in adolescence and adulthood.  
 
 
Fig 3.5. Effect of neonatal alcohol exposure on motor coordination and balance in wild 
type and MCP-1/CCR2 KO mice. Both male and female mice were exposed to alcohol 
(Ethanol) on PD4 as described in the Materials and Methods. The motor balance and 
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coordination was assessed by Balance Beam test on PD40 or PD75. The average time 
(Fig. A for adolescent male, Fig. C for adolescent female, Fig. E for adult male, Fig. G 
for adult female) and number of foot slips (Fig. B adolescent male, Fig. D for adolescent 
female, Fig. F for adult male, Fig. H for adult female) for each mouse were calculated 
from three trials. Each data point was the mean ± SEM of eight animals. # indicates a 
significant difference from the controls. p < 0.05. * indicates a significant difference from 
the Ethanol-treated group, p < 0.05. 
 
MCP-1 and CCR2 deficiency protect mice against neonatal Ethanol exposure induced 
long lasting deficits in learning and memory 
We used the Morris water maze (MWM) to assess the role of MCP-1/CCR2 in 
neonatal alcohol exposure-induced deficits on spatial learning and memory. Significant 
alterations in goal latency was observed in adolescent male mice [F(3,124) = 33.05, p < 
0.05], adolescent female mice [F(3,124) = 29.43, p < 0.05], adult male mice [F(3,124) = 
38.03, p < 0.05] and adult female mice [F(3,124) = 21.15, p < 0.05]. In addition, significant 
alterations in path length was observed in adolescent male mice [F(3,124) = 42.18, p < 
0.05], adolescent female mice [F(3,124) = 49.43, p < 0.05], adult male mice [F(3,124) = 
32.53, p < 0.05] and adult female mice [F(3,124) = 36.27, p < 0.05]. Neonatal alcohol 
exposure significantly increased the goal latency and path length for all 5 days’ trial 
compared with control group (Fig. 3.6) (p < 0.05). The KO + EtOH group showed a 
significant improvement in performance than EtOH group in both adolescence (Fig. 3.6A, 
B, E, F) and adulthood (Fig. 3.6C, D, G, H). There was no significant difference in 
performance between control group and KO group. Since we observed that neonatal 
alcohol exposure-induced motor function deficits, which may potentially affect swim 
capacity and goal latency in MWM test, we quantified and compared the swimming 
velocity of the fifth day. The fifth day is the last day of the test, the mice have gone through 
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four days of trials and have used to the MWM system, so the velocity data from the fifth 
day is a more unbiased reflection of their swimming ability. We observed that the EtOH 
group swam significantly slower than controls (p < 0.05); the KO + EtOH group showed 
a significant increase in swim velocity than EtOH group in both adolescence (Fig. 3.6I and 
J) and adulthood (Fig. 3.6K and L) (p < 0.05). Collectively, these results suggest that the 
increased goal latency in EtOH group determined by MWM could result from both 
impaired motor function and learning/memory; MCP-1 and CCR2 deletion protected mice 
against neonatal alcohol exposure-induced long lasting deficits in learning and memory as 






Fig 3.6. Effect of neonatal alcohol exposure on the spatial learning and memory in wild 
type and MCP-1/CCR2 KO mice. Both male and female mice were exposed to alcohol 
(EtOH) on PD4 as described in the Materials and Methods. The spatial learning and 
memory ability was assessed by MWM during a 5-day testing period on PD42-46 or 
PD77-81. The latency (Fig. A for adolescent male, Fig. B for adolescent female, Fig. C for 
adult male, Fig. D for adult female) and path length for finding the platform (Fig. E for 
adolescent male, Fig. F for adolescent female, Fig. G for adult male, Fig. H for adult 
female) from the four drop-off locations for each testing session during the 5-day testing 
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period were measured. The swimming velocity of the fifth day was also measured (Fig. I 
for adolescent male, Fig. J for adolescent female, Fig. K for adult male, Fig. L for adult 
female). The average goal latency, path length and swimming velocity for each mouse in 
a specific testing day were calculated from the four latencies measured from the four 
different drop-off locations. Each data point was the mean ± SEM of eight animals. # 
indicates a significant difference from the controls, p < 0.05. * indicates a significant 
difference from the Ethanol-treated group, p < 0.05. 
 
Discussion 
Previous findings from our laboratory have suggested that MCP-1/CCR2 signaling played 
an important role in ethanol-induced microglial activation/neuroinflammation and 
neurodegeneration in the developing CNS [26, 99]. We hypothesize that deficiency of 
MCP-1 and CCR2 protects mice against neonatal alcohol exposure induced behavioral 
deficits in adolescence and adulthood. In the present study, we showed that MCP-1 and 
CCR2 deficiency significantly reduced neonatal alcohol exposure-induced long lasting 
deficits in learning, memory and motor function in adolescence and adulthood in both male 
and female mice. 
It is well established that alcohol has potent effects on immune activity in the CNS 
[110-112]. Alcohol increases the expression of proinflammatory cytokines and molecules 
such as nitric oxide and COX-2 in the CNS [21, 34, 113]. A series of recent studies have 
demonstrated that the induction of an inflammatory response in the developing rodent brain 
can cause dramatic and long lasting neurobehavioral deficits in adulthood [114, 115]. 
Immune activation during early development can also alter the immune response later in 
life [114, 115].  MCP-1, also called CCL2, is a key chemokine involved in 
neuroinflammation. The biological function of MCP-1 is mediated via its G protein-
coupled receptor CCR2 [116]. CCR2 binds five pro-inflammatory chemokines: MCP-1, 
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CCL7, CCL8, CCL12 and CCL13 [117-119]. However, MCP-1 is the most potent among 
those chemokines for triggering signal transduction pathways mediated by CCR2 [120]. 
We have recently shown that ethanol induced microglial activation, neuroinflammation, 
and a drastic increase in MCP-1. MCP-1/CCR2 inhibition or MCP-1/CCR2 deficiency 
offers protection against neonatal alcohol exposure-induced microglial 
activation/neuroinflammation and neuroapoptosis in the developing brain [99].   
The current study showed that KO + EtOH group significantly improved motor 
function and coordination than EtOH group in two different testing paradigms (Rotor-Rod 
and Balance Beam) at two different ages. It is well established that third-trimester 
equivalent alcohol exposure induces long-term deficits in motor function in rodents [121-
123]. Hamilton et al observed that PD 5, 7 and 9 alcohol exposure led to long-term deficits 
on Rotor-Rod performance in adult male C57BL/6J mice [121]. Goodlett et al reported that 
rats received 4.5 g/kg daily dose of alcohol [10.2% (v/v)] from PD4 to PD9 exhibited 
significant impairment in acquiring the Rotor-Rod task and had significant reduction in 
whole brain cerebellar weight at 405 days of age [122]. Bonthius et al observed that alcohol 
treatment (2.2 or 4.4 g/kg from PD4-9) impaired performance on the Rotor-Rod and 
Balance  Beam tests and reduced cerebellar weight and Purkinje cell population in adult 
mice [123]. It is believed that the cerebellum and cerebral cortex are centrally involved in 
motor function and ethanol exposure can cause profound damage to the developing 
cerebellum and cerebral cortex [124-127]. The developing cerebellum is particularly 
vulnerable to ethanol exposure. In rodents, early postnatal ethanol exposure induces drastic 
neuronal death in the cerebellum, especially marked loss of Purkinje neurons, granule 
neurons, and deep cerebellar neurons [99, 128-131]. The cerebral cortex is also highly 
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susceptible to fetal alcohol exposure. Structural imaging reveals the frontal cortex atrophies 
and aberrant formation of the gyri and sulci due to developmental ethanol exposure [124, 
132, 133]. Functional development of neurons is also inhibited, such as impaired migration, 
delayed development of dendrites, decrease in the number of synapses, and impaired 
electrophysiological activity [134-136].  
Our current study also demonstrated that KO + EtOH group performed significantly 
better in MWM testing than the Ethanol group. This better performance is due to an 
improvement of learning and memory ability as well as swim velocity. Multiple research 
have shown that acute ethanol exposure during late mouse neurodevelopment results in 
long term deficits in memory and learning [98, 137]. Houle et al reported that mice exposed 
to alcohol at PD6 appeared to be less motivated to complete the Barnes maze at one month 
old and displayed significant deficits in spatial memory retrieval during Barnes maze recall 
at 4 month old [137]. Wagner et al reported that both the PD7 and the PD 7-9 alcohol 
treatments resulted in large and significant spatial learning impairments during MWM 
testing in adults. Typical patterns of activated caspase-3-positive neurons in the cortex, 
hippocampal formation, and striatum were also observed 6 h after the last injection on PD7 
[98]. The hippocampus is believed to play an important role in initial learning and long-
term retention of spatial memory tasks [96, 97, 138, 139] and the developing hippocampus 
of the rodent is very vulnerable to ethanol exposure. Several studies have reported a 
significant decrease in individual neuron populations in all regions of the hippocampus as 
well as neuroanatomical and electrophysiological defects in hippocampal circuitry caused 
by prenatal or postnatal ethanol exposure [140-142] 
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It is likely that the protective effects against neonatal alcohol exposure-induced 
behavioral deficits shown in our current study are offered through reducing microglia 
activation, inflammation and neurotoxicity [99]. Note that our previous study showed that 
Ethanol activated TLR4 and downstream adaptors TRIF and MyD88 and blocking MCP-
1/CCR2 signaling attenuated ethanol-induced activation of TLR4 [99]. TLR4 is a key 
mediator of microglial activation in the brain and plays an important role in ethanol-
induced neuroinflammation and neurodegeneration [71, 72, 99]. Studies have indicated 
that MyD88-deficient mice exhibit altered ethanol-induced sedation and motor impairment 
[143]. So it is possible that the protective effects against neonatal alcohol exposure- 
induced behavioral deficits shown in our current study are achieved (partially) through a 
modulation of TLR4 signaling. 
Our current research did not show a significant difference in anxiety-related 
behavior among different groups in the Open Field testing. These results are consistent 
with the ones from some previous researches [106, 137]. Houle et al reported that no 
significant differences were found in open field behavior or social responsiveness at 1 
month or 4 month of age in the mice exposed with alcohol at PD 6 [137]. However, it 
should be noted that there is controversy about the use of many of the standard tests for 
anxiety, including Open Field [144]. It is also possible that the duration of alcohol exposure 
in our model (PD4) may be insufficient to cause marked effects on anxiety-related behavior 
later in life, or this short period of exposure may miss a distinct susceptible window for 
anxiety-related behavior.  
Also note that in our current study, MCP-1 and CCR2 deficiency did not affect 
body weight. This is consistent with some previous findings. Kanda et al observed that 
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there is no significant difference in body weight, food intake, or plasma glucose 
concentrations between MCP-1 KO and WT mice maintained on the high-fat diet [145]; 
Chu et al reported that CCR2-knockout mice did not show obvious deficits in fertility, 
development or growth compared with wild-type animals when maintained in a pathogen-
free environment [146]. Also, other chemokines in the MCP-1 chemokine family (γ 
chemokine), such as CCL-1 and CCL3 may compensate MCP-1’s potential role in growth 
when MCP-1 and CCR2 are knocked out [14], which could also explain why MCP-1 and 
CCR2 deficiency did not affect body weight in our current study.  
In summary, MCP-1/CCR2 signaling plays an important role in neonatal alcohol 
exposure-induced long lasting neurobehavioral deficits. Targeting MCP-1/CCR2 can serve 
as a preventative treatment for FASD to block the emergence of adolescent and adult 












CHAPTER 4: NITRIC OXIDE MEDIATES LPS-INDUCED ENDOPLASMIC 
RETICULUM STRESS IN MICROGLIA 
Synopsis 
Background: In addition to the microglial activation and neuroinflammation, stimulation 
of MCP-1/CCR2 signaling may cause neurotoxicity through other mechanisms. For 
example, the activation of MCP-1/CCR2 signaling is reported to cause ER stress through 
the upregulation of MCPIP in cardiomyocytes and osteoclasts [147]. Kim et al.  showed 
that CCR2 inhibitor attenuated ER stress and decreased the expression of inflammatory 
cytokines in the liver of type 2 diabetic mice [148]. ER stress has recently been proposed 
as an important mechanism for ethanol-induced damage to the CNS [2, 149]. Ethanol-
induced ER stress in the developing spinal cord is significantly reduced in MCP-1−/− and 
CCR2−/−mice [26]. These studies indicate a crosstalk between ER stress and inflammation. 
In chapter 4, we sought to determine the interaction between ER stress and microglial 
activation in vitro.  
Methods: MCP-1 and LPS were used to activate SIM-A9 microglial cell line and primary 
microglia. L-NMMA was used to block NO production. The production of NO was 
quantified by measuring the released NO metabolites (nitrates and nitrites) with Griess 
colorimetric assay. 
Results: Both LPS and MCP-1 induced proinflammatory cytokines and chemokines, but 
only LPS, not MCP-1 increased the expression of ER stress markers, such as ATF6, CHOP, 
GRP 78, p-PERK, and XBP-1. Tunicamycin treatment induced ER stress but failed to 
activate microglia and increase proinflammatory cytokines. LPS but not tunicamycin 
significantly increased the production of nitric oxide (NO). L-NMMA, a nitric oxide 
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synthase (NOS) inhibitor blocked LPS-induced NO production as well as the expression 
of ER stress markers in both SIM-A9 cells and primary microglia.  
Conclusion: Our study suggests that inflammation may induce ER stress in microglia; 
however, ER stress may not activate microglia and stimulate proinflammatory molecules. 
Furthermore, NO plays an important role in LPS-induced ER stress in microglia. 
Introduction 
Neuroinflammation caused by microglial activation has emerged as a prominent 
component in the pathology of many neurodegenerative diseases, such as Alzheimer’s 
disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), Parkinson’s 
disease (PD), and alcohol-associated dementia (AAD), and fetal alcohol spectrum disorder 
(FASD) [99, 150-153]. In the central nervous (CNS), microglia are a main source of 
inflammation. Microglia constantly survey the microenvironment in response to pathogen 
or tissue damage [154]. However, increasing reports demonstrate that inflammation in the 
CNS may cause neuronal death and damage by establishing a feed-forward inflammatory 
loop [154-156].  
A hallmark of many neurodegenerative diseases is the formation of misfolded 
protein aggregates within the ER of neurons and glia [157]. The accumulation of 
misfolded/unfolded proteins could cause disturbance in the function or loss of integrity 
of the ER, which leads to ER stress [158]. ER stress has been observed in various forms 
of neurological disorders, including PD, AD, HD, ALS, and FASD [158-162]. ER stress 
induces the unfolded protein response (UPR), a homeostatic response to alleviate ER stress. 
The UPR is mediated by three main signaling pathways: the protein kinase RNA-like ER 
kinase (PERK)–eukaryotic translation initiation factor 2α (EIF2α) axis, the inositol-
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requiring protein 1α (IRE1α)– spliced X-box-binding protein-1 (XBP1s) axis, and 
activating transcription factor 6 (ATF 6) axis [163, 164]. Extracellular communication via 
cytokine and chemokine production are also involved in response to ER stress in addition 
to intracellular signaling. It has been reported that a synergistic effect between 
inflammation and ER stress may result in higher microglial activation and drive sustained 
inflammation [27]. However, it is unclear whether inflammation induces ER stress in 
microglia or reversely ER stress activates microglia and promotes inflammation. Thus, 
understanding the interplay between ER stress and microglial activation is important. In 
this in vitro study, we used LPS to activate microglia and induce inflammatory response in 
vitro; we employed tunicamycin, an inhibitor of N-linked glycosylation that blocks the first 
step of glycoprotein synthesis to induce ER stress in microglial cells. We aimed to evaluate 
the interaction between LPS-induced microglial activation/inflammation and ER stress.  
We sought to determine whether LPS could cause ER stress and conversely whether ER 
stress induced by tunicamycin treatment could activate microglia cells and induce 
inflammation. We further determined the potential mediators for LPS-induced ER stress.  
Materials and methods 
Materials  
The nitric oxide synthesis inhibitor NG-methyl-L-arginine (L-NMMA), Griess 
reagent for measuring NO metabolites nitrates and nitrites, Lipopolysaccharides (LPS), and 
tunicamycin were purchased from Sigma-Aldrich, Inc (St. Louis, MO, USA). Anti-Iba-1 
antibody was purchased from Wako Chemicals USA, Inc. (Richmond, VA, USA). Anti-
GRP78 antibody was purchased from Novus Biologicals (Littleton, CO, USA). Anti-XBP-
1 antibody was purchased from BioLegend (San Diego, CA, USA). Anti-CHOP antibody 
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was purchased from Thermo Fisher Scientific (Waltham, MA, USA). Anti-ATF6 antibody 
was purchased from LifeSpan BioSciences (Seattle, WA, USA). Anti-p-IRE1 antibody was 
purchased from Abcam (Cambridge, MA, USA). Anti-p-eIF2α and Anti-p-PERK 
antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). 
High-Capacity cDNA Archive kit and TaqMan Universal Master Mix II were purchased 
from Applied Biosystems (Foster City, CA, USA). PCR primers were purchased from 
Invitrogen (Carlsbad, CA, USA).  
Culture of microglial cells (SIM-A9) and primary mouse microglia 
Immortalized mouse microglia cells (SIM-A9) were purchased from American 
Type Culture Collection (ATCC) (Manassas, VA, USA). SIM-A9 cells are a spontaneously 
immortalized microglial cell line that exhibits key characteristics of cultured primary 
microglia [54]. The SIM-A9 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 medium supplemented with 5% horse serum, 10% fetal bovine 
serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C 
in 5% CO2 in a humidified atmosphere as previously described [99]. The culture medium 
was replaced with DMEM/F12 medium without FBS at 50-60% confluence overnight 
before indicated treatment. In order to induce inflammation, the cultures were exposed to 
LPS (2.5 ng/ml) for 24 h; in order to induce ER stress, the cultures were exposed to 
tunicamycin (3 µg/ml) for 48 h; in order to inhibit NO production, the cultures were 
exposed to L-NMMA (1mM) for 24 h.  
Primary microglial cells were cultured according to a previously described protocol 
with slight modification [165]. Briefly, meninges were removed from brains of C57BL/6 
mice at postnatal day 4. Trypsin 0.25% and DNase I were used for mincing the cerebral 
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tissue, which was filtered and resuspended in DMEM supplemented with 10% FBS and 
1% penicillin/streptomycin, and seeded in culture flasks. After 5 days in culture, astrocytes 
at the bottom of the flask formed a confluent cell layer. Microglia grew on top of the 
astrocytic layer. Microglia (floating cells) were collected by vigorously tapping the flasks 
on the bench top. Cells were seeded at 50,000 cells/cm2 in PDL-coated culture dishes and 
were used the next day.  
MTT assay 
The viability of microglial cells was determined by a 3-(4,5-dimethyl-thiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay as previously described [61]. In brief, cells 
were grown in 96 well plates in a final volume of 100 μl culture medium per well with 
indicated treatments. After incubation period, 10 μl of the MTT labeling reagent (final 
concentration 0.5 mg/ml) was added to each well. The 96 well plates were then incubated 
for 4 hours at 37°C with 5 % CO2. After that, 100 μl of the solubilization solution was 
added into each well. The spectrophotometrical absorbance of the samples was measured 
using a microplate reader 
Immunoblotting 
The proteins from SIM-A9 cells or primary microglia were extracted using 
previously described method with some modification [99]. Briefly, cells were 
homogenized and lysed in an ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 0.5% NP-40, 0.25% SDS, 5 mg/ml leupeptin, 
and 5 mg/ml aprotinin. Homogenates were centrifuged at 20,000 g for 30 min at 4°C and 
the supernatant fraction was collected. Aliquots of the protein samples were separated on 
a SDS-polyacrylamide gel by electrophoresis. The separated proteins were transferred to 
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nitrocellulose membranes. The membranes were probed with primary antibodies overnight 
at 4°C. The immune complexes were detected by the enhanced chemiluminescence 
substrate (GE Healthcare, Chalfont, Buckinghamshire, UK). The density of 
immunoblotting was quantified with the software of Image lab 5.2 (Bio-Rad Laboratories, 
Hercules, CA). 
Quantitative real-time PCR 
Total RNA was extracted from SIM-A9 cells using TRIzol reagent as previously 
described [99]. RNA concentration was determined by spectrophotometric optical density 
measurement at 260 and 280 nm. The ratio of the absorbance at 260 nm and 280 nm 
(OD260/280) was used to estimate the purity of the nucleic acid. OD260/280 in all samples 
were ~2.0. The cDNA synthesis was performed using High-Capacity cDNA Archive kit 
(Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. 
Quantitative real-time PCR (qRT-PCR) was performed using ABI 7500 Real-Time PCR 
system (Applied Biosystems). The ribosomal 18S RNA was used as an internal control. 
Results were expressed as mean fold changes of gene expression relative to control group 
using 2−ΔΔCt method. The primers used for analysis were as follows: CCR2: 5’-
GGTCATGATCCCTATGTGG-3’ and 5’-CTGGGCACCTGATTTAAAGG-3’. MCP-1: 
5’-CTTCTGGGCCTGCTGTTCA-3’ and 5’-CAGCCTACTCATTGGGATCA-3’. TNF-
α: 5’- CTGTAGCCCACGTCGTAGC-3’ and 5’-TTGAGATCCATGCCGTTG-3’. IL-6: 
5′-TCCAGTTGCCTTCTTGGGAC-3′ and 5′-GTACTCCAGAAGACCAGAGG-3′.  
Determination of nitric oxide (NO)  
NO has a short half-life and is rapidly metabolized to nitrite and nitrate in the 
presence of oxygen in plasma or other physiological fluids or buffers. The determination 
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of both nitrite and nitrate is commonly used to estimate total NO production [166, 
167]. In our study, the production of NO was quantified by measuring the released NO 
metabolites (nitrates and nitrites) with Griess colorimetric assay. After specified 
treatments, the culture medium was collected and centrifuged at a speed of 1000 rpm for 
5 min to remove the cells in the medium. After centrifugation, 50 μl of the medium was 
incubated with the same volume of Griess reagent (0.04 g/ml) at room temperature (RT) 
for 15 min in a 96 well plate before measuring absorbance at 540 nm in a microplate 
reader [168].   
 
Statistical analysis  
The data were presented as mean ± SEM. Statistical significance was determined 
by the ANOVA followed by Tukey’s post hoc test. Differences in which p was < 0.05 were 
considered statistically significant. 
Results 
LPS activates microglia and induces ER stress  
LPS is a well-known activator of microglia and induces proinflammatory cytokines 
and chemokines, such as TNFα, IL-6 and MCP-1 [169-172]. We treated SIM-A9 
microglial cells with 2.5 ng/ml of LPS to activate these cells and induce inflammation as 
previously reported [54]. We confirmed that LPS increased the protein levels of TNFα, IL-
6, and microglial cell marker Iba-1 (Fig. 4.1A). To determine whether LPS caused ER 
stress, we examined the expression of a spectrum of proteins involved in the UPR (Fig. 
4.1B). LPS significantly increased the expression of 78 kDa glucose-regulated protein 
(GRP 78) [F(3,8)=24.85, p<0.05], phosphorylated eIF2α (p-eIF2α) [F(3,8)=16.74, 
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p<0.05], phosphorylated PERK (p-PERK) [F(3,8)=17.51, p<0.05], the spliced form of X-
box binding protein 1 (XBP1S, 55KD) [F(3,8)=16.26, p<0.05], inositol-requiring enzyme1 
(IRE1) [F(3,8)=31.63, p<0.05] and C/EBP Homologous Protein (CHOP) [F(3,8)=7.52, 
p<0.05]. The increase in those ER stress markers peaked at 24 h after LPS treatment. The 
LPS treatment did not affect the cleaved form of ATF 6 protein (ATF6N, 60KD) protein 
expression, suggesting that LPS-induced ER stress was mainly through PERK–EIF2α and 
IRE1α–XBP1s signaling pathways, but not the ATF6 pathway. Note that MCP-1 has been 
recently reported to induce microglial activation and inflammation in neurons [99, 173], 
we also treated the microglial cells with 10 ng/ml MCP-1 for 24 h [99], however, MCP-
1 did not significantly alter the expression of ER stress markers in cultured microglial 
cells (Fig. 4.1C). 
 
Fig. 4.1. Effect of LPS on the expression of proinflammatory cytokines and ER stress 
markers in cultured microglia cells. A. SIM-A9 microglial cells were exposed to LPS (2.5 
ng/ml) for 6, 12 and 24 h. The expression of Iba-1, TNFα and IL-6 were determined by 
immunoblotting (IB) and quantified by the normalization to the expression of actin. B. The 
expression of GRP 78, p-eIF2α, p-PERK, XBP1S, CHOP, and ATF6N were determined 
by IB and quantified by the normalization to the expression of actin. C. The expression of 
GRP 78, p-PERK, p-IRE1 and ATF6 were determined by IB. Each data point was the mean 
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± SEM of three independent experiments. *p < 0.05, statistically significant difference 
from 0 h control. 
 
Tunicamycin causes ER stress but does not induce inflammatory responses in 
microglial cells 
We next sought to determine whether ER stress induces inflammatory responses in 
SIM-A9 cells. Tunicamycin is an N-linked glycosylation inhibitor and commonly used to 
induce ER stress experimentally [174]. We examined the effect of tunicamycin on cell 
viability and protein expression of ER stress markers. The concentrations of tunicamycin 
selected in our study were based on previous reports [175-177]. Tunicamycin treatment at 
3 µg/ml of significantly reduced cell viability at 24 h and 48 h compared with control 
[F(2,6)=4.59, p<0.05] (Fig. 4.2A). Tunicamycin also drastically increased the expression 
of GRP78, ATF6N, p-PERK and p-IRE-1 in SIM-A9 cells (Fig. 4.2B). These results 
indicate that tunicamycin induced ER stress in SIM-A9 cells. However, unlike LPS, 
tunicamycin did not affect the transcription of MCP-1, TNFα and IL-6 (Fig. 4.2C). The 
results suggests that ER stress caused tunicamycin may not activate and trigger 
inflammation in cultured microglial cells.  
Fig. 4.2. Effect of tunicamycin on the expression proinflammatory cytokines and ER stress 
markers in cultured microglia cells. A. SIM-A9 cells were treated with tunicamycin (0.5 
µg/ml, 1 µg/ml or 3 µg/ml) for 24 h and 48 h. The cell viability was determined by MTT 
as described in the Materials and Methods. B. SIM-A9 cells were treated with tunicamycin 
(3 µg/ml) for 48 h, the expression of GRP78, ATF6N, p-PERK and p-IRE-1 were 
determined by IB and quantified by the normalization to the expression of actin. C. SIM-
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A9 cells were exposed to tunicamycin (3 µg/ml) or LPS (2.5 ng/ml) for 48 h. The mRNA 
levels of MCP-1, TNFα, and IL6 were determined by quantitative PCR described in the 
Materials and Methods. Each data point was the mean ± SEM of three independent 
experiments. *p < 0.05, statistically significant difference from controls. 
 
Nitric oxide (NO) is involved in LPS-induced ER stress in microglia.  
We next determined the mechanisms underlying LPS-induced ER stress in 
microglia. Since NO has been recently proposed to involve in ER stress [178], we 
hypothesized that NO may mediate LPS-induced ER stress in microglia. As shown in Fig. 
3A, LPS but not tunicamycin drastically increased NO production. We used L-NMMA, 
an inhibitor of NOS to inhibit the generation of NO from arginine [179, 180]. 
Pretreatment of L-NMMA at 1 mM blocked LPS-induced increase in NO production 
[F(4,10)=8.25, p<0.05] (Fig. 4.3A). The concentration of L-NMMA used in this study 
was based on previous reports [179, 180]. More importantly, L-NMMA significantly 
inhibited LPS-induced increase of ER stress markers in SIM-A9 cells [GRP78: 
F(3,8)=12.65, p<0.05; p-IRE-1: F(3,8)=14.32 p<0.05; p-PERK: F(3,8)=13.87 p<0.05] 
(Fig. 4.3B) and primary mouse microglia [GRP78: F(3,8)=17.33, p<0.05; p-IRE-1: 
F(3,8)=11.76 p<0.05; p-PERK: F(3,8)=12.83 p<0.05] (Fig. 4.3C). These results indicate 




Fig. 4.3. Effect of L-NMMA on the expression of ER stress markers in SIM-A9 cells and 
primary microglia. A. SIM-A9 cells were pretreated with L-NMMA (1 mM) for 24 h 
prior to LPS (2.5 ng/ml) or tunicamycin (3 µg/ml) treatment for 24 h. The production of 
NO was quantified by measuring the released NO metabolites (nitrates and nitrites) as 
described in the Materials and Methods. SIM-A9 cells (B) and primary microglia (C) were 
pretreated with L-NMMA (1 mM) for 24 h prior to LPS (2.5 ng/ml) treatment. After LPS 
treatment for 24 h, cells were harvested and the expression of GRP78, p-IRE-1, and p-
PERK was determined by IB. Each data point was the mean ± SEM of three independent 
experiments. *p < 0.05, statistically significant difference from LPS-treated group; #p < 
0.05, statistically significant difference from control group.  
Discussion 
In this study, we showed that LPS activated microglial cells, and increased NO 
release as well as the expression of proinflammatory cytokines and chemokines. LPS also 
caused ER stress which was evident by the elevated expression of ER stress markers 
GRP78, p-eIF2α, p-PERK, XBP1, and CHOP. Tunicamycin, an ER stress inducer, caused 
ER stress but did not cause inflammation in microglial cells. Furthermore, blocking NO 
formation by L-NMMA reduced LPS-induced ER stress in microglial cells, suggesting 
that NO was involved in LPS-induced ER stress. 
ER stress and neuroinflammation are two important hallmarks of 
neurodegenerative diseases. The accumulation of misfolded proteins within the ER of 
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neurons and glial cells are commonly observed in many neurodegenerative diseases [181, 
182]. In response to ER stress, cells induce UPR in an attempt to maintain homeostasis 
[183]. The activation of the UPR orchestrates transcriptional and translational changes in 
the cell to minimize stress and increase the adaptive capacity of the ER within the brain 
[184-187]. However, prolonged ER stress developed in neurodegenerative diseases is 
believed to disrupt the protective mechanisms of the UPR, leading to the activation of 
apoptotic programs that promote neurotoxicity. For example, Chronic ER dysfunction is 
highly associated with the memory and cognitive manifestations in AD [188]; Post-mortem 
analysis revealed that phosphorylated PERK co-localized with α-synuclein within 
dopaminergic neurons derived from PD patients [189]; GRP78 and CHOP are significantly 
upregulated in the white matter of multiple sclerosis (MS) patients [190].  
Immune activation is observed in various neurodegenerative diseases [151, 153, 
173]. Microglia and astrocytes constitute the resident immune cells of the CNS and play 
an important role in maintenance of brain plasticity in development, aging and 
neurodegenerative diseases [191, 192]. In the CNS, microglia constantly survey the 
microenvironment in preparation for insult or injury by producing factors that influence 
surrounding astrocytes and neurons [193]. Although microglia activation in response to 
pathogen or tissue damage could further engage a self-limiting response through the 
immune system and initiates tissue repair [154], inflammation may result in the production 
of neurotoxic factors, which amplifies the disease states [194, 195]. Although both ER 
stress and neuroinflammation are involved in neurodegeneration, the relationship between 
ER stress and neuroninflammation is unclear.  
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LPS is a well-established stimulant that activates microglia, resulting in 
neurotoxicity by releasing pro-inflammatory cytotoxic substances, including NO, TNFα, 
IL6, and MCP-1 [171, 172, 196-198]. NO is produced from the amino acid L-arginine by 
the members of the NO synthase (NOS) family of proteins (iNOS or NOS2). iNOS and 
NOS2 can be induced in microglial cultures upon treated with proinflammatory cytokines 
or bacterial endotoxin, such as LPS [199-201]. NO has a short half-life and is rapidly 
metabolized to nitrite and nitrate in the presence of oxygen [202]. Nitrite and hydrogen 
peroxide can oxidize tyrosine by peroxidases to form nitrotyrosine, a marker of nitrosative 
stress [203]. NO is involved in several cellular functions, including neurotransmission, 
regulation of the immune response and influences both cellular constituents of the blood 
and vascular smooth muscle [204].  
In the CNS, NO is a neurotransmitter and NO production is associated with 
cognitive function, pain perception, control of sleep, appetite, thermoregulation, neural 
development and synaptic plasticity [205-207]. Although low local concentrations of NO 
have been shown to offer neuroprotection through heme oxygenase [208] or S-nitrosylation 
[209], excessive NO production is in part responsible for glutamate neurotoxicity in 
neurons and in multiple neurodegenerative diseases [204, 210-212]. In primary brain 
cultures, Dawson et al observed that NO is responsible, at least in part, for NMDA-type 
glutamate neurotoxicity [212]. In neurodegenerative disorders, excessive NO production 
is a common feature and NO is believed to be much more harmful when involving the 
production of reactive oxygen species (ROS), such as superoxide anions [205, 213]. 
Several studies observed the formation of nitrotyrosine in AD and PD patients [205, 214, 
215]. In HD, an excessive production of NO might cause neuronal death and contribute to 
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the pathogenesis of HD [216]. Nitrate and nitrite levels are significantly higher in CSF 
compared to serum in MS patients [217], which could be the consequence of a BBB 
dysfunction mediated by NO [218].   
In addition to its involvement in neuroinflammation, NO has also been recently 
proposed to participate in ER stress. Kawahara et al reported that NO-induced apoptosis in 
murine microglial MG5 cells occurred through the ER stress pathway involving CHOP 
[219]; Renna et al observed that NO induced ER stress in J774 macrophages and activated 
the expression of cargo receptor proteins [220]; Brozzi et al reported that NO plays a key 
role in cytokine-induced ER stress in rat islets [178]; a different study using murine 
pancreatic β cells also confirmed NO-induced apoptosis is mediated by the ER stress 
pathway [221]; In addition, NO has been demonstrated to play an important role in the 
regulation of mitochondrial function and ER stress in pluripotent stem cells [222].  
We showed here that LPS stimulated NO release from microglial cells. L-NMMA 
is an NOS inhibitor which blocks the biosynthesis of NO from arginine [223, 224]. 
Pretreatment with L-NMMA blocked LPS-induced increase in NO production and ER 
stress markers, indicating that LPS-induced ER stress in microglia was, as least in part, 
mediated by NO. Tunicamycin caused ER stress; however, it did not induce 
proinflammatory cytokines, chemokines, and NO, suggesting that ER stress was down-
stream of inflammation in microglial cells. In conclusion, NO played an important role 
in LPS-induced ER stress in microglia. The findings provide a new insight into the 




CHAPTER 5. DISCUSSION AND FUTURE DIRECTION  
FASD is the leading cause of mental retardation in North America, ahead of Down 
syndrome and cerebral palsy [225-228]. FASD is estimated to affect as many as 5% of 
people in the United States and some Western European countries, and the economic 
burden of FASD in the US is significant [229]. The developing CNS is particularly 
susceptible to alcohol exposure, so even moderate maternal drinking could lead to 
cognitive and behavioral impairments [225, 230-233]. Despite attempts to raise awareness 
about the dangers of drinking during pregnancy, numbers of women drinking during 
pregnancy in the USA have not declined [30].  
Microglial activation and neuroinflammation have been implicated in alcohol 
neurotoxicity in the developing CNS [6, 26, 35, 62, 99]. It has been proposed that 
microglia primed by ethanol exposure may lead to excess neuroinflammation and the 
subsequent neurotoxicity observed in AUD and FASD [6, 35]. Since MCP-1/CCR2 plays 
an important role in microglial activation and neuroinflammation, I investigated the 
involvement of MCP-1/CCR2 in alcohol neurotoxicity in the developing brain. In the 
third trimester equivalent mouse model of alcohol exposure, alcohol caused widespread 
neuroapoptosis, microglial activation and neuroinflammation in the brain. MCP-1 
synthesis inhibitor Bindarit and CCR2 antagonist RS504393 each significantly inhibited 
alcohol-induced microglial activation/neuroinflammation and neuroapoptosis in the brain 
of early postnatal mouse pups. Moreover, alcohol and MCP-1 caused more neuronal 
death in the neuron/microglia co-culture system than the neuronal culture alone, 
suggesting that microglia are required for alcohol/MCP-1-induced neurotoxicity. Bindarit 
and RS504393 effectively protected neurons against alcohol/MCP-1-induced neuronal 
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death in the co-cultures, indicating that MCP-1/CCR2 signaling is involved in microglial 
contribution to ethanol neurotoxicity. In addition, we observed that ethanol activated 
TLR4 and GSK3β, two key mediators of microglial activation in the brain and cultured 
microglial cells (SIM-A9). Blocking MCP-1/CCR2 signaling attenuated ethanol-induced 
activation of TLR4 and GSK3β. 
There are several important implications from this study. The current finding 
establishes an important role of GSK3β in microglial activation and neuroinflammation. 
We have previously demonstrated that ethanol-induced activation of GSK3β in neurons 
may cause neurodegeneration in the developing brain and in vitro [234]. Our recent study 
showed that minocycline inhibited GSK3β and offered protection against ethanol 
neurotoxicity in the developing brain [62]. Together, these findings suggest that the 
activation of GSK3β in both neurons and microglia contributes to ethanol neurotoxicity, 
although it may operate by different mechanisms. It will be worthy investigating the 
potential role of GSK3β as a therapeutic target for the treatment of ethanol neurotoxicity 
in the developing CNS. 
In order to evaluate the role of MCP-1 and CCR2 signaling in neonatal alcohol 
exposure induced long lasting behavioral deficits, I performed a series of behavioral tests 
including Open Field, Rotor-Rod, Balance Beam, and Morris Water Maze (MWM) in the 
adolescent and adulthood mice. Compared to wild-type mice, MCP-1-/-/CCR2-/- mice were 
more resistant to neonatal alcohol exposure-induced deficits in general motor function and 
coordination which were determined by Rotor-Rod testing and Balance Beam testing. 
MCP-1 and CCR2 deficiency also protected mice against neonatal alcohol exposure- 
induced long lasting deficits in learning and memory which was determined by MWM.  
70 
 
Multiple research have identified specific brain regions, such as prefrontal cortex, 
cerebellum, hippocampus, amygdala, and thalamus of particular interest due to their roles 
in motor function, learning, memory and anxiety [124-127]. So it will be important to 
evaluate morphological changes in brain structures that correspond to the behavioral 
changes in our study. Besides, it is well established that microglia plays an important role 
in neurogenesis [235, 236] and third trimester EtOH exposure could lead to reduced 
neurogenesis, which may lead to abnormal neuro-behavioral manifestations prevalent in 
preterm infants [237]. Therefore, it will worth investigating the role of MCP-1/CCR2 on 
developmental EtOH exposure induced impaired neurogenesis. In addition, alcohol 
exposure prenatally may sensitize the immune system to subsequent insult and lead to 
excess neuroinflammation, neurotoxicity, and the development of alcohol-related disorders 
such as adult alcoholism. It will be interesting to investigate neuroinflammatory activity in 
a time-course after ethanol exposure to determine whether anti-MCP-1/CCR2 treatment in 
an extended therapeutic window after ethanol exposure will prevent long-term behavioral 
deficits 
In addition to the microglial activation and neuroinflammation, stimulation of 
MCP-1/CCR2 signaling may cause neurotoxicity through other mechanisms. For example, 
the activation of MCP-1/CCR2 signaling is reported to cause ER stress through the 
upregulation of MCPIP in cardiomyocytes and osteoclasts [147]. Kim et al. showed that 
CCR2 inhibitor attenuated ER stress and decreased the expression of inflammatory 
cytokines in the liver of type 2 diabetic mice [148]. ER stress has recently been proposed 
as an important mechanism for ethanol-induced damage to the CNS [2, 149]. Ethanol-
induced ER stress in the developing spinal cord is significantly reduced in MCP-1−/− and 
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CCR2−/−mice [26]. These studies indicate a crosstalk between ER stress and inflammation. 
I therefore sought to determine the interaction between ER stress and microglial activation 
in vitro. LPS was used to activate SIM-A9 microglial cell line and primary mouse 
microglia. LPS induced proinflammatory cytokines and chemokines, and increased the 
expression of ER stress markers, such as ATF6, CHOP, GRP 78, p-PERK, and XBP-1. 
Tunicamycin, an inhibitor of N-linked glycosylation, was used to induce ER stress. 
Tunicamycin treatment induced ER stress but failed to activate microglia and increase 
proinflammatory cytokines. LPS but not tunicamycin significantly increased the 
production of nitric oxide (NO). L-NMMA, a nitric oxide synthase (NOS) inhibitor 
blocked LPS-induced NO production as well as the expression of ER stress markers in both 
SIM-A9 cells and primary microglia. Our study suggests that inflammation may induce ER 
stress in microglia; however, ER stress may not activate microglia and stimulate 
proinflammatory molecules. Furthermore, NO plays an important role in LPS-induced ER 
stress in microglia. 
Multiple mechanisms regarding NO induced ER stress have been proposed. NO-
related species may contribute to protein misfolding through protein S-nitrosylation [238-
240]. It is also reported that disturbance of Ca2+ homeostasis is involved in NO-induced 
ER stress pathway activation [221, 241]. So it will be interesting to elucidate the molecular 
mechanisms underlying NO-mediated ER stress in microglia. In addition, the current 
study was carried out in vitro. It will be important to determine whether LPS or other 
proinflammatory inducers cause ER stress in microglia in vivo, and whether NO is 
involved in this process in animal models.  
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